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PART I
Unfulfilled needs and poor practices relating to pharmaceutical 
products applied in paediatrics in daily clinical practice

1
Introduction
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The development of medicines for children has long been a neglected area. Until late 
into the 20th century, the general view was that, for ethical reasons, children should not 
be subjected to clinical research. Nowadays, the consensus is that children are entitled 
to medicines that have been appropriately evaluated for their use, but other barriers 
still remain. As the paediatric population from premature neonate to adolescent is 
very heterogeneous, it cannot be approached as a uniform group. This brings not only 
practical issues in study design, but the smaller populations also mean a lower returns on 
investment for companies. As a result, a paucity exists in medicines designed and studied 
for use in children. On a European level, at the end of 2006, of the 317 centrally authorised 
medicines, 43% had a potential paediatric use, but were not authorised in this manner (1). 
European legislation and incentives for the development of paediatric medicines
Within the European Union, this paucity in paediatric medicines was acted upon by 
specific legislation in the form of the Paediatric Regulation (EC No 1902/2006), following 
the example of the US Best Pharmaceuticals for Children Act. When this regulation came 
into effect in 2007, one of the first measures that were taken was the establishment of 
the Paediatric Committee, with its main role of scientific assessments and agreement of 
paediatric investigation plans (PIP). Since then, all applications for marketing authorisation 
for new medicines have to include the results of studies as described in an agreed PIP, unless 
the medicine is exempt because of a deferral or waiver. This has resulted in 949 agreed PIPs 
by the end of 2016, of which 131 had been completed (2). Between the adoption of the 
Paediatric Regulation in 2007 and the end of 2016, 101 of 399 (26%) centrally authorised 
new medicines received a paediatric indication. The Paediatric Regulation is therefore 
seen as successful, but the above applies mainly to innovative medicines, and does not 
include the development of off-patent medicines. 
To stimulate the development of off-patent medicines for paediatric patients, several 
measures were taken. Firstly, the Paediatric Use Marketing Authorisation (PUMA) was 
established by Article 30 of the Paediatric Regulation. It is an incentive for off-patent 
medicinal product development for paediatric use, which offers 10 years of data and 
marketing protection. Secondly, specific European funding for research into off-patent 
medicinal products was made available, for instance through the EU Framework 
Programmes for Research and Technological Development. Thirdly, an inventory of 
paediatric needs was made, which is published on the EMA website (3), and is meant to 
help developers identify opportunities. It consists of lists of medicines by therapeutic 
class, which identify needs with respect to clinical data and age appropriate formulations. 
From these lists, it is evident that there is a great lack of age-appropriate formulations for 
off-patent medicines. Unfortunately, up to 2018, only four PUMAs have been granted (4), 
and it seems that the data and marketing protection is not an effective incentive. 
The role of pharmacists in supplying paediatric patients with age-appropriate 
formulations
Even though the development of new medicines has improved greatly since the 
introduction of the Paediatric Regulation, there are many therapeutic areas in which 
there is still a need for paediatric formulations of older medicines. When age-appropriate 
licensed formulations are not available, pharmacists have several options in providing 
paediatric patients with suitable preparations. The most preferred option would be to seek 
a licensed therapeutic alternative. Examples of drug classes where substitution is common 
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are proton pump inhibitors and NSAIDs. Importation of products that are authorised 
in another EU country is a second option, but this can be time consuming and costly, 
and is often subject to strict regulations, which are country-specific. In the Netherlands, 
reimbursement is also difficult for non-licensed imported products.  A third option is 
the compounding of medicines within the pharmacy, defined as the preparation of an 
unlicensed medicine to meet the specific needs of a patient. This can either be using raw 
materials, or the authorised dosage form. These three options are much preferred above 
the alternative; the manipulation of licensed  dosage forms, such as splitting or crushing 
of tablets, or mixing with fluids or food, by parents and caregivers. With this option, the 
risk of quality issues is probable, and bioavailability may be substantially altered. When 
crushing Kaletra (lopinavir/ritonavir) tablets for example, lopinavir and ritonavir exposure 
in children reduced by 45% and 47%, respectively (5). 
Officially, two types of pharmacy preparations are recognised in Directive 2001/83/
EC, known as magistral formulae (any medicinal product prepared in a pharmacy in 
accordance with a medical prescription for an individual patient) and officinal formulae 
(any medicinal product which is prepared in a pharmacy in accordance with the 
prescriptions of a pharmacopoeia and is intended to be supplied directly to the patients 
served by the pharmacy in question). In The Netherlands, as in several other European 
Member States, an alternative practice is common, where centralised, GMP-certified 
pharmacies manufacture unlicensed medicines and supply them to local pharmacies. 
Although in conflict with Directive 2001/83/EC, it is officially allowed by the Health and 
Youth Care Inspectorate because of the obvious improvement in pharmaceutical quality 
it provides, but it is tightly regulated. 
Practices concerning compounding/manufacturing of unlicensed paediatric formulations 
and the facilities and equipment available to pharmacists are highly variable across the 
European Union.  In an effort to standardise quality and availability throughout the EU, 
initiatives are currently undertaken towards the compilation of a pan-European Paediatric 
Formulary, consisting of monographs for extemporaneous formulations, based on 
national or regional information. Led by the European Committee on Pharmaceuticals and 
Pharmaceutical Care (CD-P-PH) and the European Pharmacopoeia Commission, a working 
party of European experts is currently working on the selection and elaboration of the 
formulations to be included (6). It is expected that the Formulary of Dutch Pharmacists 
(FNA) will contribute largely to this Paediatric Formulary.
Paediatric product development
Most of the unlicensed products dispensed to paediatric inpatients are manufactured 
at GMP-pharmacies, and are thus based on pharmaceutical quality data and extensive 
product dossiers. This also applies to the two drug products presented in this thesis, 
which were designed at the pharmacy of the Erasmus MC and studied in association 
with the Laboratory of Dutch Pharmacists (LNA). The LNA is a department of the Royal 
Dutch Pharmacists Association and supports pharmacist in the compounding of essential 
medicines of good quality, when licensed products are not available. 
The starting point of product development for new paediatric products is always the 
clinical need. Generally, therapeutic rationale has been established, but the available 
dosage forms fall short. The EMA has offered some guidance for the selection of dosage 
forms in relation to the acceptability by paediatric patients, summarised in a reflection 
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paper (7). One of the main considerations is the ability to deliver the correct dose to 
the patient. Within the heterogeneous paediatric population, this means that dosing 
flexibility is required for a specific drug, and it reduces the options to low-dose solid 
dosage forms, liquids or parenteral formulations. In the inpatient setting, as a large 
proportion of the patients is below the age of two or is dependent on a feeding tube, 
liquid formulations are usually the first choice if non-parenteral administration is aimed 
for. In addition to the standard drug and formulation properties such as dosage strength, 
solubility, taste and stability, certain aspects of the formulation need specific attention 
when designing a product for paediatric patients, in particular the choice of excipients. 
The EMA guideline on pharmaceutical development of medicines for paediatric use (EMA/
CHMP/QWP/805880/2012) offers useful guidance for the selection of excipients, and a 
hierarchized list of information sources to consult in order to assess the safety profile of 
each one. Another important property to consider is the palatability of the excipients and 
the drug product as a whole. Palatability, a combination of taste, after-taste, mouth-feel, 
fragrance and appearance, is one of the main elements determining the acceptability of 
paediatric medicinal products (8). 
In vitro evaluation of paediatric products
Currently, most officinal formulae that are compounded or manufactured in the 
Netherlands and applied in paediatrics, have not been clinically evaluated. This has led 
to unexpected deviations in exposure to the drug in multiple occasions, an example 
being the reduced oral bioavailability of tacrolimus suspension, compared to tacrolimus 
capsules (9).  Ideally, in the future, in vivo performance of oral dosage forms in children can 
be predicted with use of in vitro biopharmaceutical techniques. Unfortunately, the drug 
absorption processes in children have not yet been sufficiently elucidated to develop and 
validate accurate biopharmaceutical methods.
In vivo studies
When formulation development has been completed, sometimes it is necessary evaluate 
the product  in vivo. A general principle is that paediatric patients should be given 
medicines that have been appropriately evaluated for their use. Unnecessary clinical trials 
in (paediatric) patients should however be avoided. From a regulatory perspective, a new 
formulation that has not been tested in efficacy trials, requires a bioequivalence study, 
which should typically be performed in adults (10).  
Bioequivalence studies are performed to make sure that two formulations have the same 
rate and extent of absorption (within predefined limits), to ensure comparable in vivo drug 
exposure. The parameters area under the curve (AUC), maximum plasma concentration 
(Cmax) and sometimes time to maximum plasma concentration (tmax), are calculated from 
dense sampling schemes and compared between formulations. Bioequivalence studies 
may however be exempted, if in vitro data can be expected to adequately predict the 
in vivo performance. These so-called biowavers are based on the Biopharmaceutic 
Classification System (BCS, Figure 1). The BCS is a system to differentiate drugs on the basis 
of their solubility and permeability (11). A drug is considered highly soluble when the 
highest dose strength is soluble in 250 ml or less of aqueous media over the pH range of 
1 to 7.5. A drug is considered highly permeable when the extent of absorption in humans 
is determined to be 90% or more of the administered dose based on a mass-balance 
determination or in comparison to an intravenous dose. BCS class 1 (highly soluble and 
14 Chapter 1
highly permeable) and sometimes class 3 drugs (highly soluble and low permeable) are 
eligible for biowaivers. Additional conditions for a biowaiver are rapid dissolution and 
similar excipients, if they might affect the bioavailability. 
Figure 1.1 Biopharmaceutical classification system. The x-axis shows the volume (ml) required to 
dissolve the highest dose strength of the drug at the lowest solubility over the pH range 1–7.5. 
Permeability is defined by various in vivo or in vitro assays. A drug is considered highly permeable 
when the extent of oral absorption in humans is determined to be 90% or more of the administered 
dose based on a mass-balance determination or in comparison to an intravenous dose.
When it comes to paediatric formulations, there are some limitations to this approach. 
Both the parameters solubility and permeability may not be extrapolated to paediatric 
population. Consequently, BCS-based biowaivers, as well as adult bioequivalence studies, 
need to be regarded with caution in the paediatric setting. 
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Aims and outline of this thesis
This thesis we describe the work that was carried out towards a framework for the 
development of paediatric oral liquids and their evaluation in the target population. 
In part one of this thesis we aimed to identify the unfulfilled needs and poor practices 
relating to pharmaceutical products applied in paediatrics in daily clinical practice. It has 
two main focus points: firstly, the availability and suitability of drug products for paediatric 
patients, and secondly, the practical issues regarding administration of drug products to 
paediatric patients. In chapter 2 we describe studies into the drug products that were 
dispensed from the pharmacy and assessed their suitability for the specific patient 
according to EMA guidelines. Furthermore, we identified liquid drug products that are 
unsuitable due to the presence of potentially harmful excipients, based on the extent of 
exposure. In chapter 3 we surveyed the extent of manipulation of drug products required 
to adequately administer the drug to the patient. Both parents and nurses were involved 
in the study, using questionnaires (parents) and observation (nurses) as main methods. 
The second part of this thesis contains the formulation development that was conducted 
in collaboration with the Laboratory of Dutch Pharmacists. For children, oral liquid 
formulations with acceptable palatability, good pharmaceutical quality and possibility of 
flexible dosing are still urgently needed. As a proof of concept, two drugs were selected, 
both frequently used in children; amlodipine representing a typical BCS class I drug, and 
lorazepam as an example of a drug with poor aqueous solubility. In chapter 4 we describes 
the pharmaceutical development of an amlodipine 0.5 mg/ml oral liquid, and chapter 5 
proposes a liquid formulation for poorly soluble compounds with lorazepam as a proof 
of concept. Chapter 6, which was a collaboration with the University of Bath, explores in 
vitro biopharmaceutical methods that could be used to predict formulation performance 
in paediatric patients. 
In the third part of this thesis we present the clinical studies that were conducted following 
the pharmaceutical development of the two experimental formulations. Chapter 7 
contains the results of a bioequivalence trial in adults of commercial amlodipine tablets 
and the oral liquid described in chapter 4. This liquid was subsequently studied in the 
target population using a population pharmacokinetic design. The retrospective study 
in chapter 9 evaluates the effects of an IV midazolam to oral lorazepam conversion on 
withdrawal and sedation levels on the paediatric intensive care unit. The subsequent 
clinical trial in which the bioavailability and pharmacokinetics of our lorazepam oral liquid 
is studied is described in chapter 10. 
Finally, the results, conclusions and recommendation from the studies described in this 
thesis are discussed in a summarizing discussion. 
16 Chapter 1
REFERENCES
1. European Medicines Agency with 
its Paediatric Committee. 5-year Report to 
the European Commission: General report 
on the experience acquired as a result of 
the application of the Paediatric Regulation. 
London: European Medicines Agency, 2012 
Contract No.: EMA/428172/2012.
2. European Commission. State of 
Paediatric Medicines in the EU - 10 years of the EU 
Paediatric Regulation. Brussels 2017 26.10.2017. 
Report No.:  Contract No.: COM(2017) 626 final.
3. European Medicines Agency. 
Paediatric medicines - Needs for paediatric 
medicines London [Available from: 
http : //w w w.ema.europa.eu/ema/index.
j s p ? c u r l = p a g e s / re g u l at i o n / d o c u m e nt _
l i s t i n g / d o c u m e n t _ l i s t i n g _ 0 0 0 0 9 6 .
jsp&mid=WC0b01ac0580925b1e.
4. European Medicines Agency with 
its Paediatric Committee. 10-year Report to 
the European Commission: General report 
on the experience acquired as a result of 
the application of the Paediatric Regulation. 
London: European Medicines Agency, 2017 
Contract No.: EMA/231225/2015.
5. Best BM, Capparelli EV, Diep H, Rossi 
SS, Farrell MJ, Williams E, et al. Pharmacokinetics 
of lopinavir/ritonavir crushed versus whole 
tablets in children. J Acquir Immune Defic Syndr. 
2011;58(4):385-91.
6. European Directorate for the Quality of 
Medicines and Healthcare. European Paediatric 
Formulary: Background & Mission Strassbourg: 
Counsil of Europe; 2018 [Available from: https://
www.edqm.eu/en/background-mission-1.
7. Committee for Medicinal Products 
for Human Use (CHMP). Reflection paper: 
formulations of choice for the paediatric 
population. London: 2006.
8. Walsh J, Ranmal SR, Ernest TB, Liu 
F. Patient acceptability, safety and access: A 
balancing act for selecting age-appropriate 
oral dosage forms for paediatric and geriatric 
populations. Int J Pharm. 2018;536(2):547-62.
9. Reding R, Sokal E, Paul K, Janssen 
M, Evrard V, Wilmotte L, et al. Efficacy and 
pharmacokinetics of tacrolimus oral suspension 
in pediatric liver transplant recipients. Pediatr 
Transplant. 2002;6(2):124-6.
10. European Medicines Agency. ICH 
Topic E 11 Clinical Investigation of Medicinal 
Products in the Paediatric Population. . London: 
2011  Contract No.: CPMP/ICH/2711/99.
11. Amidon GL, Lennernas H, Shah 
VP, Crison JR. A theoretical basis for a 
biopharmaceutic drug classification: the 
correlation of in vitro drug product dissolution 
and in vivo bioavailability. Pharm Res. 
1995;12(3):413-20.



PART II
Pharmaceutical development and in vitro evaluationof the formulations

4A.C. van der Vossen
I. van der Velde
O.S.N.M. Smeets
D.J. Postma
A. Vermes
B.C.P. Koch
A.G. Vulto
L.M. Hanff
Design and stability study of an oral 
solution of amlodipine besylate for 
pediatric patients 
Eur J Pharm Sci. 2016 Sep 20;92:220-3.
56 Chapter 4
ABSTRACT
Introduction
Amlodipine is an antihypertensive agent recommended for the management of 
hypertension in children and adolescents. The commercially available tablets of 5 and 10 
mg do not provide the necessary flexibility in dosing needed for treating children. Our 
goal was to develop a pediatric oral solution of amlodipine, using a robust manufacturing 
process suitable for ex-tempora and larger scale production.
Methods
The parameters API and preservative content, related substances, appearance and pH 
were studied under four different storage conditions. Samples were analyzed up to 12 
months. Microbiological quality was studied in an 18-week in-use test based on a two-
times daily dosing schedule. 
Results
The stability of the formulation was influenced by storage conditions and composition. A 
formulation containing amlodipine besylate, sucrose syrup and methyl paraben remained 
physically stable for 12 months at 4°C with no loss of amlodipine content. Related 
substances increased during the study but remained below 0.5%. In-use stability was 
proven up to 18 weeks.
Discussion
Storage under refrigerated conditions was necessary to prevent precipitation and to obtain 
an acceptable shelf-life. In conclusion, we have developed and validated an amlodipine 
oral solution, suitable for the pediatric population. This liquid formulation is preferred 
over manipulated commercial dosage forms or non-standardized extemporaneously 
compounded formulations.
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INTRODUCTION
Amlodipine (3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-
methyl-1,4-dihydropyridine-3,5-dicarboxylate) is a long-acting dihydropyridine L-type 
calcium channel blocker widely used in both adults and children. It selectively inhibits 
calcium ion influx in vascular smooth muscle and cardiac muscle, thereby inhibiting 
the contractile processes of these tissues. The resulting peripheral arterial vasodilation 
and reduction in peripheral vascular resistance reduces the arterial blood pressure (1). 
Currently, amlodipine is one of the antihypertensive agents recommended by the 
European Society of Hypertension for the management of hypertension in children 
and adolescents (2). Within the group of calcium channel blocking agents, amlodipine 
is considered first choice treatment for chronic hypertension in children, because of its 
pharmacological characteristics and it being the most extensively studied drug within this 
class (2, 3). Calcium channel blockers are also specifically recommended as the preferred 
drug class in pediatric posttransplantation hypertension (2).
Amlodipine is prescribed off-label to children from the age of 1 month in a dose of 0.06-
0.3 mg/kg per day (2). Using the commercially available tablets of 5 and 10 mg, these 
dosages cannot be administered accurately in young children. Amlodipine has therefor 
been added to the ‘Inventory of paediatric therapeutic needs’ published by the European 
Medicines Agency (EMA), as there is no age-appropriate formulation available (4). 
According to the EMA reflection paper on pediatric formulations, an oral liquid dosage 
form would generally be the form of choice and best applicable to administer systemic 
medication to infants and toddlers (1m-2y) and young children (2-5y). If the physical and 
chemical characteristics as well as the taste of the drug substance are appropriate, solutions 
are preferred over suspensions due to better oral acceptance. In addition, solutions are 
less susceptible to dosing errors resulting from insufficient re-dispersion and are easier to 
administer through an enteral feeding tube. Further properties that need to be taken into 
account when designing a pediatric oral liquid dosage form are dose volume (preferably 
≤ 5mL for children under 5 years) and use of child-friendly excipients (5).
Since amlodipine is slightly soluble in water (6, 7) and not prone to chemical degradation 
when protected from light (8), an oral solution might be a feasible dosage form. Its 
pharmacokinetic characteristics make a once-daily dosing schedule possible, without the 
need for a controlled release formulation (9). This aids in compliance and acceptability by 
pediatric patients (10). 
For amlodipine only extemporaneously compounded suspensions have been formulated, 
using commercially available generic suspension bases (Ora-Plus®/Ora-Sweet® 1:1 and 
Syrspend® SF) and crushed tablets or amlodipine besylate raw material, resulting in a 
limited stability of 3 months (8, 11, 12). In The Netherlands, as well as in other EU countries, 
centralized officinal production of unlicensed medicines by GMP-certified pharmacies is 
common practice. These products are supplied to other pharmacies, after which they are 
dispensed to the patient.  Simultaneously, a  part of the community pharmacies still has 
compounding facilities to provide ex-tempora formulations to their own patients. This 
situation requires a formulation design that provides an acceptable shelf-life for batch-
production, but at the same time allows for individual ex-tempora compounding.
Our goal was to develop and validate a pediatric oral solution of amlodipine, using a 
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robust manufacturing process (suitable for extemporaneous compounding). To maximize 
affordability of and accessibility to the formulation, we chose to make use of manufacturing 
methods suitable for individual and larger scale production. 
MATERIAL AND METHODS 
Initially an attempt was made to develop a solution of 1 mg/mL amlodipine besylate, 
preserved with methyl paraben 0.15% and buffered with citric acid. The aqueous solubility 
of amlodipine was so low that it required heat to dissolve and precipitated shortly after 
preparation. Lowering  the amount of methyl paraben or citric acid buffer did not improve 
the stability. The concentration of amlodipine was then lowered to 0.5 mg/mL (equal to 
0.69 mg/mL amlodipine besylate), which is an acceptable concentration for application in 
clinical practice. 
Composition
The starting point for the comprehensive development of our formulation was an 
aqueous solution containing amlodipine besylate. Methyl paraben was maintained 
as a preservative, since it is considered suitable for use in pediatric formulations (13). 
Because we aimed for a shelf-life of at least six months, preservative-free formulations 
were not considered. To enhance the taste of the formulation, sucrose syrup was added 
until an acceptable taste achieved, according to our experienced formulation developers 
(Composition A). Additional artificial flavors were omitted to preclude a negative influence 
on the physical stability. Because of the limited aqueous solubility of amlodipine, a second 
formulation containing propylene glycol as a co-solvent was studied (composition B). 
Thirdly, a formulation containing amlodipine maleate (Composition C) was studied, to 
examine if the aqueous solubility of the maleate form would be better. All formulations 
were manufactured in batches of 2500 mL (A and B) or 5000 mL (C) and put into 100 
mL, amber-colored polyethylene terephthalate (PET) (A, B and C) or glass containers 
(C). Composition A was prepared with active pharmaceutical ingredient (API) from two 
suppliers (Duchefa and Wyeth), so four batches of amlodipine solution were manufactured, 
of which the compositions can be found in Table 4.1. Amlodipine besylate, maleate and all 
other excipients were European Pharmacopoeia grade. 
Long-term stability studies
The influence of temperature, packaging material and amlodipine salt form on long term 
stability were investigated. Samples were stored in climate cabinets at 4±2°C (Elbanton 
type 5KV-2-50), 25±2°C (Elbanton type LC 500) and 40±2°C (Elbanton type LTKB-ST650). 
In each cabinet the temperature was registered hourly. Samples of composition A and 
C were additionally stored at ambient temperature and indirect daylight. Influence of 
packaging material was studied on composition C, samples were stored in PET and glass 
containers under each storing condition. API and preservative content were examined 
over time. Initially, we aimed for a shelf life of 6 months. Samples were analyzed at 0, 1, 
2, 3 and 6 months. With an extension of the stability studies, samples stored at 4°C were 
subsequently also analyzed at 9 ant 12 months. 
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Table 4.1 Compositions of the studied formulations, which were manufactured in batches of 2500 
mL (A and B) or 5000 mL (C) and put into 100 mL, amber-colored polyethylene terephthalate (PET) 
(A, B and C) or glass containers (C).
 
Composition A
Amlodipine besylate 69 mg
Methyl paraben solution 15% m/v* 287 mg
Sucrose syrup^ 32 g
Purified water 75,137 g
107,51 g (=100 mL)
Composition B
Amlodipine besylate 69 mg
Methyl paraben solution 15% m/v* 432 mg
Sucrose syrup^ 10 g
Propylene glycol 3,796 g
Purified water 88,133 g
102,43 g (=100 mL)
Composition C
Amlodipine maleate 64 mg
Methyl paraben solution 15% m/v* 304 mg
Sucrose syrup^ 32 g
Purified water 75,442 g
107,81 g (=100 mL)
 
*Methyl paraben is processed as a 15% m/v solution in propylene glycol.  
^ Sucrose syrup contains 63% m/v sucrose and 0,1% m/v methyl paraben
The stability indicating HPLC-UV method for determination of API, related substances and 
preservative content was modified from the Ph. Eur. method of amlodipine besylate drug 
substance by introduction of a gradient in the mobile phase. Analytical specifications can 
be found in Table 4.2. Release and end-of-shelf-life specifications are displayed in Table 
4.3. 
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Table 4.2 Analytical specifications of the stability indicating HPLC-UV assay of amlodipine oral 
solution, derived from the Ph. Eur. monograph of amlodipine besylate.
Column Spherisorb ODS1, 5 µm, 250 x 4.0 mm
Test solution 20 µL of 2 ml amlodipine besilate oral liquid in 18 ml water R 
Reference solution 20 µL of 0.05 mg/ml amlodipine as besilate in 1:9 methanol R and water R 
Wavelength 237 nm
Flow 1.5 ml/min
Temperature 30°C
Mobile phase A: 2.3 g/L ammonium acetate R in water R
B: Methanol R
Gradient Time (min.) Solution A (%) Solution B (%)
0 50 50
5 50 50
6 30 70
35 30 70
36 50 50
45 50 50
In-use stability
An in-use test was performed on Composition A based on a two-times daily dosing 
schedule. Based on the results from the stability studies, the containers were stored at 
4°C and twice-daily removed from the climate chamber to be exposed to air, light and 
ambient temperature for 30 minutes at every dosing simulation. Samples of 0.4 mL were 
withdrawn until a quantity of 25 mL remained after which the dosing simulation continued 
without taking samples. After 18 weeks the samples were analyzed in accordance with the 
specifications in Table 4.3.
Manufacturing procedure
The amlodipine drug substance was added to ca. 60% of the total volume of distilled water. 
Using a magnetic stirrer and heating up to 50°C, amlodipine dissolved completely. Methyl 
paraben solution 15% m/v was added and the mixture was stirred vigorously using the 
magnetic stirrer. The mixture was cooled to ambient temperature and the sucrose syrup 
was added. Finally distilled water was added to the solution to reach the desired volume. 
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Table 4.3 Release and end-of-shelf-life specifications amlodipine besylate solution 0.5 mg/mL. 
Microbiological tests of the formulation were performed in two samples from the finished in-use 
stability study. 
Test Item Method Reference Acceptance Criteria
Identification According to assay Ph. Eur. Amlodipine 
Monograph 
Spectra should be iden-
tical to reference
Assay (API and 
preservative)
HPLC-UV Modified Ph. Eur. meth-
od
90% ≤ content ≤ 110%
Related sub-
stances
HPLC-UV Modified Ph. Eur. meth-
od
Total related substances 
≤ 1.5%
Appearance Visual observation Ph. Eur. 2.2.1 Clarity ≤ O1
Ph. Eur. 2.2.2 Coloration  < GY6
pH pH meter Ph. Eur. 2.2.3 Range 5.0 – 6.5
Microbiological 
quality
Milliflex Plus 
0,45 μm funnel 100 mL
TSA Casette
In-house procedure TAMC ≤ 102 CFU/mL
Ph. Eur. = European Pharmacopoeia; TAMC = Total aerobic microbial count
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RESULTS
Stability studies
The physical and chemical stability of the amlodipine solutions were influenced by the 
storage conditions. At 25°C and 40°C, resulting from both precipitation and chemical 
degradation, amlodipine content declined over time as displayed in Figure 4.1. Results 
after six months for Composition A and B are displayed in Table 4.4. A gradual increase 
in related substances was seen in all samples, but was notably higher with increasing 
temperatures. 
Table 4.4 Results from the stability studies at 6 months. 
 
Storage con-
dition and 
composition Appearance pH
Am-
lodipine 
content
Preser-
vative 
content
Related 
sub-
stances
Clarity1 Color2 Particles (%) (%) (%)
T=0 A ≤ O1 <GY6 - 5.9 100.0 95.6 <0.1
B ≤ O1 <GY6 - 5.7 98.8 95.3 <0.1
T=6 4˚C A ≤ O1 <GY6 - 5.8 99.2 94.9 <0.1
B ≤ O1 <GY6 - 5.6 97.5 95.1 0.2
25˚C A ≤ O1 <GY6 + 5.6 92.0 95.6 2.1
B ≤ O1 <GY6 + 5.4 90.9 96.1 1.8
40˚C A < O3 <GY6 + 4.6 55.3 93.7 4.0
B < O2 <GY6 + 4.8 58.3 95.3 3.2
Ambient 
condi-
tions
A NA NA NA NA 94.1 95.4 1.5
 
1 Refer to Ph. Eur. 2.2.1 
2 Refer to Ph. Eur. 2.2.2. 
NA; not available
Based upon the stability results at six months, the stability studies were continued with 
composition A, since the addition of propylene glycol to Composition B did not provide 
any advantages. During the extended stability studies, Composition A remained physically 
stable for 12 months at 4°C with an amlodipine content of 98.7% (see Figure 4.1) and total 
related substances of 0.5% (not shown). At ambient temperature, the formulation was 
physically stable for at least two months. 
In Composition C particles were first seen after two weeks at 40°C. Crystal depositions 
were visible in both PET and glass containers. After 3 weeks particles were also seen in 
Composition C stored at 25°C. The stability studies of Composition C were at this point 
discontinued. 
No changes in color and clarity were observed in any of the samples before precipitation 
occurred. The methyl paraben content did not decrease in any of the formulations during 
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the stability studies. 
Figure 4.1 Amlodipine besylate content over time for Composition A and B under different storing 
conditions. After six months stability studies were continued with the preferred composition A. 
In-use stability
The samples of Composition A remained physically stable during the in-use study, no 
crystal depositions of amlodipine were formed. Both the content of amlodipine and 
methyl paraben increased with 6-8% as a result of evaporation of water. The related 
substances reached a maximum of 0.2%. The total bacteria count was less than 100 cfu/
mL at week 18 of the in-use study in all samples. 
DISCUSSION
In this study, we developed an oral solution of amlodipine besylate with adequate physical 
and chemical stability, a shelf-life of 12 months and excipients suitable for pediatric 
patients. 
The biggest challenge in the development of the formulation was the poor aqueous 
solubility of amlodipine. The Ph. Eur. describes amlodipine besylate as ‘slightly soluble 
in water’, which would mean that it has a solubility of 1 to 10 mg/mL. This is consistent 
with the solubilities submitted by Pfizer in the US patent (14). In our pre-studies, a stable 
aqueous solution of 1 mg/mL or higher appeared not to be feasible, therefore we reduced 
the concentration to 0.5 mg/mL. Storage under refrigerated conditions was necessary to 
prevent precipitation and to obtain an acceptable shelf-life. With precipitation occurring 
faster at higher temperatures, it appears to be an endothermal process.
The addition of propylene glycol (Composition B) to enhance the solubility did not 
provide any advantages in the physical stability of the product. Since propylene glycol can 
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be a harmful excipient for pediatric patients (15), we decided to discontinue the stability 
studies with Composition B after 6 months. The substitution of  amlodipine maleate for 
amlodipine besylate did not improve the stability of the formulation.
Due to the unpleasant taste of amlodipine besylate, we had to increase the amount 
of sucrose syrup above the recommended range of 10-20% required for acceptable 
palatability (16). Although the use of cariogenic sweeteners, such as sucrose, should 
be restricted for chronic use in pediatric formulations, acceptance of the formulation 
will highly depend on how it tastes (14). The sucrose syrup concentration was therefore 
considered to be acceptable. The palatability of our formulation was later surveyed in a 
bioequivalence study in healthy adult volunteers, and on average rated between “not 
good, not bad” and “good” (17). 
In conclusion, we have developed a well-validated amlodipine oral solution, suitable 
for the pediatric population and able to provide the required dosing flexibility. This 
formulation is preferable to manipulated commercial dosage forms and non-standardized 
extemporaneously compounded formulations. It is suitable for large-scale production 
as well as extemporaneous compounding, which is in many situations necessary for the 
pediatric population. Our formulation has already proven to be bioequivalent to 5 mg 
tablets (17) and is now being studied in the pediatric population in order to construct a 
population pharmacokinetic model.
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ABSTRACT 
Introduction
Many drugs are unavailable in suitable oral paediatric dosage forms, and pharmacists often 
have to compound drugs to provide paediatric patients with an acceptable formulation 
in the right dose. Liquid formulations offer the advantage of dosing flexibility and ease 
of administration to young patients, but drug substances often show poor aqueous 
solubility. The objective of this work was to study different solvents and matrices to design 
a liquid formulation for poorly water soluble drugs, using lorazepam as model drug.
Methods
Three different formulation strategies were explored to improve the solubility. Firstly, 
water-soluble organic solvents were used to improve the aqueous solubility directly, 
secondly, ionic surfactants were used to solubilise the model drug, and thirdly, 
complexation of lorazepam with cyclodextrin was studied. Specific attention was paid to 
excipients, adequate taste correction and palatability. For the final formulation, physical 
and chemical stability and microbiological quality were assessed for 12 months. 
Results
An organic solvent based formulation, containing a mixture of polyethylene glycol and 
glycerol 85%, with a minimum amount of propylene glycol, proved to be physically 
and chemically stable. Development of the non-ionic surfactants formulation was 
discontinued due to taste problems. The cyclodextrin formulations were physically 
stable, but lorazepam content declined to 90% within five months. The final formulation 
contained in volume concentration (%v/v) 87% glycerol, 10% polyethylene glycol 400 and 
3% propylene glycol. Orange essence was the preferred taste corrector. The formulation 
remained stable for 12 months at 4°C, with lorazepam content remaining > 95%. Related 
substances increased during the study period but remained below 2%. In-use stability 
was proven up to 4 weeks. 
Conclusion 
An organic solvent based oral formulation was shown to be superior to a non-ionic 
surfactant based formulation or a cyclodextrin formulation. These results may help to 
formulate paediatric formulations of other poorly water soluble drugs, to aid pharmacy 
compounding.
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INTRODUCTION
Many drugs are unavailable in suitable oral paediatric dosage forms (1), therefore, 
pharmacists often have to compound drugs to provide paediatric patients with an 
acceptable formulation in the right dose. In the reflection paper released by the paediatric 
working party of the European Medicines Agency (EMA) on formulations of choice for 
the paediatric population, solutions/drops and effervescent dosage forms are considered 
to have the highest applicability in a population of young patients (2). Capsules can be 
compounded extemporaneously in the dosage needed, but they need to be dissolved 
before administration and are difficult to administer through feeding tubes. Another 
disadvantage of extemporaneously compounded capsules is the difficulty in obtaining 
adequate content uniformity at low dosages. 
Liquid formulations have the advantage of dosing flexibility and a reduced risk of choking. 
They can also be applied in other populations, such as geriatric patients with swallowing 
difficulties, or in a palliative setting. Possible disadvantages of liquid formulations are 
issues with stability and palatability, parameters that need to be considered in the design. 
As an alternative for liquid formulations, the development of mini-tablets has been 
given a lot of attention in the past years (3). They provide dosing flexibility and ease of 
administration, and generally solid formulations are more stable than liquid formulations. 
However, for most compounding pharmacies, tableting is not an available technique. 
Liquid formulations are therefore still commonly applied by pharmacist that need to 
compound for paediatric patients, both on individual and batch scale.
Drug substances sometimes show poor aqueous solubility. The use of solubilizing 
excipients can improve this, but especially in the paediatric population, the use of 
excipients needs to be considered carefully, with respect to safety and palatability. The 
objective of this study was to explore different formulation strategies for a poorly water 
soluble drug substance, lorazepam was chosen as a model drug. 
Lorazepam (7-chloro-5-(2-chlorophenyl)-3-hydroxy-2,3-dihydro-1H-1,4-benzodiazepin-2-
one) is a benzodiazepine indicated for the treatment of generalized anxiety disorder and 
pre-surgical anxiety in patients from the age of twelve years (4). Off-label, it is applied in a 
wide range of indications and patient categories, because of its sedative and anticonvulsive 
activity and absence of active metabolites. Within paediatrics, it is administered to 
children from the age of one month for acute anxiety, sedation, chemotherapy induced- 
or associated nausea, status epilepticus or for weaning purposes (5). 
Currently, no liquid dosage form of lorazepam is available in the EU. An extemporaneous 
suspension of 1 mg/mL, prepared from 2 mg tablets, distilled water, Ora-Plus® and Ora-
Sweet®, has been proven to be chemically stable for up to three months when stored at 4°C 
(6). However, a subsequent study using this suspension proved that dosage measurement 
by paediatric intensive care nurses led to significant deviations from the intended dose 
(7). These inaccurate dosage measurements are less likely to occur in the case of an oral 
solution, but the physical and chemical characteristics of lorazepam make this a challenge. 
There are different strategies to formulate a poorly water soluble drug substance into an 
oral solution. pH Adjustment can be used to ionize a compound, which generally will result 
in increased aqueous solubility. In the case of lorazepam (aqueous solubility 0.08 mg/
ml) (8), with pKas of 1.3 and 11.5 (9), pH adjustment is not a feasible method to increase 
the solubility. It is also sensitive to hydrolysis in both acidic and basic environments (10) 
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and shows temperature-dependent degradation (11). Organic solvents can be used as an 
alternative to water, but specific attention has to be paid to safety in paediatric patients. 
A distinction can be made between water-soluble and water-insoluble organic solvents. 
Water-soluble co-solvents, like ethanol (lorazepam solubility 14 mg/ml) and propylene 
glycol (lorazepam solubility 16 mg/ml) (8), create a mixed aqueous/organic solution. These 
excipients are readily available and easy to process, but they can convey a risk of toxicity 
to children (2). A combination of water-insoluble organic solvents, such as medium-
chain and long-chain triglycerides and oleic acid, can be used to disperse lipophilic 
drugs. Alternatively, a poor water-soluble drug can be solubilized using surfactants, like 
polysorbate 20 and 80 (Tween) or polyoxyl hydrogenated castor oil (Cremophor), to 
obtain micelles in an aqueous environment. Similarly, surfactants can be used to obtain 
a microemulsion, when combined with a polar solvent, an oil, and a cosurfactant. Lastly, 
complexation of poorly soluble drugs with cyclodextrins has been a strategy to increase 
the aqueous solubility and bioavailability of compounds, while at the same time masking 
the taste (12), an important aspect in the design of paediatric formulations. 
The objective of this study was to explore different formulation strategies to process 
a poorly soluble drug substance into a clear oral solution, using lorazepam as a model 
drug. The formulation needed to be suitable for paediatric patients from the age of one 
month, and have adequate stability to allow for individual and batch production within 
the pharmacy. 
MATERIAL AND METHODS 
Materials
Lorazepam drug substance was bought from Fagron BV (Capelle a/d IJssel, The Netherlands) 
and Duchefa Farma BV (Haarlem, The Netherlands). Lorazepam related compound B and 
hydroxypropyl-β-cyclodextrin (HP-β-CD, substitution degree 0.6) were bought from 
Sigma-Aldrich Chemie BV (Zwijndrecht, The Netherlands). Lorazepam related compounds 
C and D were bought from USP Switzerland (Basel, Switzerland). Colour Reference 
Solutions Y were bought from Merck Millipore (Amsterdam, The Netherlands). Lorazepam 
drug substance and all other excipients were European Pharmacopoeia grade.
Formulation development
The dosage strength was chosen based on the target population of children from the age 
of one month to 18 years old, receiving a maximum dose of 0.6 mg/kg/day (5). To limit the 
volume needed and excipients administered, we aimed for a strength of 1 mg/ml. Three 
different formulation strategies were explored to improve the solubility. Firstly, water-
soluble organic solvents were used to improve the aqueous solubility directly, secondly, 
non-ionic surfactants were used to solubilise the model drug, and thirdly, complexation 
of lorazepam with cyclodextrin was studied. Parameters that were studied were; physical 
stability (by visual inspection), chemical stability, using the analytical assay described in 
section 2.5, and palatability (see 2.3). Physical instability was defined as the presence of 
visible precipitation. The visual inspection of the samples was performed according to Ph. 
Eur. 2.2.1., with use of commercial reference solutions. The physical and chemical stability 
were initially studied for 5 months. 
Organic solvents
For the organic solvents-based formulation, we experimented with different ratios of 
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propylene glycol (PG), poly ethylene glycol 400 (PEG400) and glycerol 85%. Efforts were 
directed towards a glycerol/PEG400 based mixture containing minimal amounts of 
propylene glycol (Figure 5.1). 
O1 O2 O3 O4 O5 O6 O7
Glycerol 85% 0,8 0,73 0,75 0,77 0,83 0,85 0,87
PEG 400 0,1 0,2 0,2 0,2 0,1 0,1 0,1
Propyleenglycol 0,1 0,07 0,05 0,03 0,07 0,05 0,03
0
0,2
0,4
0,6
0,8
1
Co
nt
en
t (
%
)
Lorazepam 1mg/ml test formulations
Water-soluble organic solvents
Figure 5.1 Lorazepam 1 mg/ml test formulations containing water-soluble organic solvents.
Non-ionic surfactants
The second strategy that was explored was the use of non-ionic surfactants to create a 
micellar solution. Polysorbate 80 and sorbitan monooleate were mixed in a ratio to obtain 
a hydrophilic/lipophilic balance (HLB) of 11.5. The total surfactant content in the test 
formulations ranged from 1-5%. PEG400 was used to dissolve lorazepam, after which the 
micellar solution was slowly added to the PEG400. The volume per test formulation was 50 
mL, the composition of the excipients is displayed in Figure 5.2. 
S1 S2 S3 S4 S5 S6
Polysorbate 80 1,697 0,338 0,674 1,005 1,254 1,697
Sorbitan monooleate 80 0,785 0,162 0,293 0,49 0,667 0,785
PEG400 1,014 2,61 2,51 2,48 2,52 2,51
0
1
2
3
4
5
6
Co
nt
en
t (
g)
Lorazepam 1mg/ml test formulations (50 ml)
Non-ionic surfactants
Figure 5.2 Lorazepam 1 mg/ml test formulations containing non-ionic surfactants. 
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Cyclodextrin
For the cyclodextrin formulation, HP-β-CD was chosen as the complexing agent, because 
of its high water solubility, lower cost compared to other cyclodextrins, low toxicity 
(12), and based on previous work investigating different cyclodextrins for inclusion 
complexation of lorazepam (13). A phase solubility diagram was made to measure the 
solubility of lorazepam as a function of the HP-β-CD concentration. This revealed that a 
minimum of 54 mg/mL HP-β-CD was required to obtain a 1 mg/ml lorazepam solution 
after 4 hours of ultrasonification. However, a HP-β-CD solution of 60 mg/mL (formulation 
C1) proved not sufficient to maintain a stable product after one week, therefor the HP-β-
CD concentration was increased to 100 mg/ml (formulation C2). Glycerol 85% was added 
as a preservative in an amount of 35% m/v. 
Palatability
The palatability of the test formulations was assessed by three adults, experienced in 
taste assessment. Characteristics that were evaluated were smell, taste, aftertaste and 
mouthfeel, and they were independently and qualitatively described by the taste panel. 
Taste correction possibilities were assessed with formulation C2, O6 and O7, using lemon, 
banana, raspberry and orange essence. Raspberry and banana were chosen as they are 
regularly applied in paediatric formulations. Lemon and orange flavours are good taste 
maskers for bitter drug substances. 
Long-term stability studies
After the preliminary formulation studies, a decision was made to continue the 
development with formulation O7 (Table 3). To this end, two batches of 3000 ml each 
were compounded, to investigate the influence of temperature and packaging material 
on long term stability. The test formulations were prepared with active pharmaceutical 
ingredient (API) from two different suppliers (Fabbrica Italiana Sintetici S.p.A and Cambrex 
Profarmaco Milano S.r.l.). Samples were stored in climate cabinets at 4 °C (VTL650K, range 
2-8 °C) and 25°C 60% relative humidity (Elbanon type LC 500, range 23-27 °C, 55-65% RH) 
in amber-coloured polyethylene terephthalate (PET) and glass containers. In each cabinet 
the temperature was registered hourly. Because of the known temperature dependent 
degradation of lorazepam, stability studies at 40°C were omitted. Samples were tested 
against the release or end-of-shelf life specifications, based on the United States 
Pharmacopeia (USP) monograph for lorazepam oral concentrate and the general Ph. 
Eur. monograph for microbiological quality of non-sterile pharmaceutical preparations, 
shown in Table 5.1. Samples stored at 25°C were analysed at 0, 1, 2, and 3 months. Samples 
stored at 4°C were also analysed at 6, 9 and 12 months. 
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Table 5.1 Release and end-of-shelf life specifications.
Test Item Method Reference Acceptance criteria
Identification According to assay Ph. Eur. Lorazepam 
Monograph
Spectra should be identical to 
reference
Appearance Visual Observation Ph. Eur. 2.2.1 Clarity ≤ Susp. I
Ph. Eur. 2.2.2 Coloration ≤ Y5
Assay HPLC-UV Modified Ph. Eur. 
method
Lorazepam 90-110%
Related compound C ≤ 4%
Sum of other related com-
pounds ≤ 2%
Microbiological 
quality
Bioburden filtration Ph. Eur. 2.6.1. E. Coli Absent
TAMC (CFU/mL) < 100
TYMC (CFU/mL) < 10
CFU = Colony-forming unit; TAMC = Total aerobic microbial count; TYMC = Total combined yeasts/
moulds count
Analytical assay
For the quantitative analysis of lorazepam and lorazepam related compounds (USP) 
B, C and D [2-amino-2,5’-dichlorobenzophenone, 6-chloro-4-(o-chlorophenyl)-2-
quinazolinecarboxaldehyde and 6-chloro-4-( o-chlorophenyl)-2-quinazolinecarboxylic 
acid, respectively] a high performance liquid chromatography combined with UV (HPLC-
UV) detection method was used. The components were separated using a Shimadzu LC20 
system, on a C18 analytical column (Inertsil ODS-3.5 µm 150x4.6 mm) with a mixture of 
acetonitrile, methanol and ammonium acetate solution (100 mM, pH 6.0 ± 0.04 adjusted 
with 1 M acetic acid) in the ratio 1:1:1 (v/v/v) as mobile phase, at a flow rate of 1.0 mL/
min. Column temperature was kept at 30 ± 0.1°C and UV detection for quantification was 
performed at 230 nm using a Shimadzu M20A diode array detector, while the wavelength 
range of 200-400 nm was continuously monitored for unidentified peaks. The injection 
volume was 20 µl. The method was validated for the quantification of lorazepam in the 
cyclodextrin and PG/PEG 400/glycerol sample matrices and in the presence of related 
compounds B, C and D, for the parameters shown in Table 5.2. The response factors of 
related compounds B, C and D were determined to allow for accurate quantification of 
these compounds on lorazepam calibration curves. 
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Table 5.2 Validation parameters of the developed HPLC-UV analytical assay. 
Parameter Test n Specification Result
Accuracy (12.5 - 37.5 µg/mL) Recovery (%) 12 98.0 - 102.0 100.0
Coefficient of variation (%) 12 < 1.0 0.5
Linearity (0 - 1.25 µg/mL) F-value (12;1 p=0.05) 14 < 4.747 1.508
Correlation coefiicient 14 > 0.9950 0.9978
Linearity (12.5 - 37.5 µg/mL) F-value (10;1 p=0.05) 12 < 4.965 2.050
Correlation coefiicient 12 > 0.9950 0.9997
Limits LLOQ (µg/mL) 26 - 0.055
LOD (µg/mL) 26 - 0.018
Intra-assay precision (0.25 µg/
mL) Coefficient of variation (%) 6 < 1.0 0.2
Intra-assay precision (25 µg/mL) Coefficient of variation (%) 6 < 1.0 0.1
Inter-assay precision (25 µg/mL) Coefficient of variation (%) 6 < 2.0 1.4
Response factors Related compound B 4 - 0.707
Related compound C 4 - 1.085
Related compound D 4 - 0.999
Specificity Lorazepam (%) 2 > 99.5 99.7
Related compound B (%) 2 > 99.5 99.9
Related compound C (%) 2 > 99.5 99.8
Related compound D (%) 2 > 99.5 99.6
 
LLOQ lower limit of quantification, LOD limit of detection
Calibration and sample analysis
Samples were diluted 40 times to 25 µg/mL with mobile phase and quantified on a 
calibration curve (20–30 µg/mL) of freshly prepared standard solutions of lorazepam RS 
in mobile phase using the validated HPLC method. All duplicate sample analyses were 
preceded by a system suitability test consisting of replicate (n=5) injections of an equal 
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mixture of lorazepam RS 25 µg/mL in mobile phase and lorazepam related compound 
D, 25 µg/mL RS in mobile phase. Specifications for the relative standard deviation in the 
lorazepam peak areas and the resolution between the lorazepam and lorazepam related 
compound D peaks were ≤0.5% and 3.8-4.6, respectively. If unavailable, lorazepam related 
compound D can be created in situ by diluting a lorazepam RS 1000 µg/mL solution in 
methanol 40 times with 1 M sodium hydroxide and exposing it to a temperature of 70°C 
for two hours, then neutralized by mixing with an equal volume of 1 M hydrochloric acid.
In-use stability
An in-use test was performed on the final formulation (O7) based on a four-times daily 
dosing schedule. The containers were stored at 4°C (range 2-8°C) and based on the 
application in our PICU, four-times daily removed from the climate chamber to be exposed 
to air, light and ambient temperature for 15 minutes at every dosing simulation. Samples 
of 0.25 mL were withdrawn. After 28 days the samples were analysed in accordance with 
the specifications in Table 5.1. Microbiological quality was tested in accordance with the 
bioburden filtration method of Ph. Eur. 2.6.1.
Manufacturing procedure
The manufacturing procedure was developed with the intention to be suitable for 
individual and batch compounding. The lorazepam drug substance was levigated in a 
mortar with the solvent mixture. The remaining solvent was added by geometric dilution. 
Orange essence was added and the solution was magnetically stirred for one hour to 
achieve complete solution of the lorazepam. 
RESULTS
Formulation development
The organic solvents-based formulations O1-O7 all resulted in physically stable products 
for at least 5 months. In formulation O1-O4, the lorazepam content declined to around 
80-90% after 5 months at 4°C. Formulations O5-O7 were also chemically stable, with 
lorazepam content remaining around 100% after five months at 4°C. For this reason, 
we chose formulation O7, with the lowest propylene glycol content, to take into further 
development (Table 5.3).
Table 5.3 Composition of the lorazepam formulation studied for long-term and in-use stability.
Lorazepam 100 mg
Poly Ethylene Glycol 400 10 g
Propylene Glycol 3 g
Orange Essence 100 mg
Glycerol 85% ad 108,1 g (=100 ml)
The surfactant-based formulations gave variable results. Formulations S1-S3 precipitated 
within a few days (S1) to two months (S3). Formulations S4-S6 remained physically stable 
during the study period. The content of S4 declined towards the end-of-shelf life limit of 
90% within 3 months at 4°C. S5 and S6 remained chemically stable, but development of 
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these formulations was discontinued due to the bad soapy taste of the liquid.
The cyclodextrin formulation C2 containing 100 mg/ml HP-β-CD remained physically 
stable during the 5 month study period. The lorazepam content declined to around 90% 
after 5 months at 4°C with formation of related substance C up to 2,9%. 
Palatability
The taste assessment results within the panel were consistent. Both cyclodextrin 
formulations had a neutral scent, slightly sweet taste, and a faint bitter taste caused by 
the lorazepam. There was no obvious aftertaste, but a prickly sensation on the tongue was 
sometimes observed. The lemon essence was the preferred taste corrector for formulation 
C2. Formulations S4 and S4 both had an overpowering soapy smell and taste, which was 
the reason for discontinuing the development of the surfactant-based formulations. 
All organic solvent-based formulations had a neutral scent, a sweet taste and a bitter 
aftertaste. Formulations with 20% PEG400 had a stronger bitter taste than formulations 
with 10% PEG400. Orange essence was the preferred taste corrector for formulation O6 
and O7. 
Long-term stability
The long-term chemical stability studies of formulation O7 showed that lorazepam 
content declined over time as displayed in Figure 5.3. A gradual increase in related 
compounds, mainly related compound C, was seen in all samples, but was notably higher 
at 25°C. Therefore, stability studies at 25°C were stopped after 3 months. At 12 months, 
related compound B was first measured in the 4°C samples and also an unknown impurity 
was found. Related compound C remained below 2.0%. The packaging material did not 
influence the chemical degradation of lorazepam. No changes in colour and clarity were 
observed in any of the samples.
Figure 5.3 Average lorazepam content (left graph) with SD (n=4) and related compound C content 
(right graph) with SD (n=4) of formulation O7 at 4 and 25 °C . 
In-use stability
The samples of formulation O7 remained stable during the in-use study, no visual changes 
were observed. The content of lorazepam did not decrease during the in-use study. 
Related substance C reached a maximum of 0.5% and the remaining related substances 
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were all below the quantification limit. The total aerobic microbial count and total yeast 
and mould counts were <1 colony forming unit per sample (the total remaining liquid per 
vial) at day 28 of the in-use study in all samples. 
DISCUSSION
In this study, we explored different formulation strategies to compound a poorly water-
soluble drug into a clear oral liquid formulation, using lorazepam as a model drug. With the 
intended application in paediatric patients, specific attention was paid to child-friendly 
excipients and adequate palatability. We developed an oral solution of lorazepam at a 
concentration of 1 mg/ml with adequate physical and chemical stability, and a shelf-life of 
at least 12 months. This clear solution can be expected to provide good dosing accuracy. 
In our final, organic solvent based formulation, a small volume (3% m/v) propylene glycol 
was still needed to ensure adequate stability. Recently the European Medicines Agency 
has published a new assessment report concerning the safety of propylene glycol in 
paediatric formulations (14). In this report, new safety limits were set, expressed in terms 
of maximum daily doses that are considered to be safe whatever the duration and the 
route of administration. For neonates up to 28 days, this limit is set at 1 mg/kg, for children 
1 month to 4 years old it is set at 50 mg/kg, and for children aged five years and up it is 
set at 500 mg/kg. Even in the rare occasion that the maximum dose of 0.6 mg/kg/day is 
required, the intake limits for patients above 28 days old will not be reached with our 
formulation. If administration to neonates is required, the propylene glycol limit of 1 mg/
kg/day may be exceeded, and therefore its use is not recommended for neonates.
In the last decades, an increasing amount of research has been performed into 
cyclodextrins as a pharmaceutical excipient. The best known example of cyclodextrin in 
a commercial formulation, is itraconazole (Trisporal®) 10 mg/ml oral solution, containing 
40% HP-β-CD and 2,5% propylene glycol, which is used off-label in children. HP-β-CD 
seems to be a promising option for a lorazepam solution. However, our results showed a 
restricted stability of maximum of 5 months, most likely due to hydrolysis of lorazepam. 
The compounding method, needing 4 hours of ultrasonification, proved impractical for 
individual preparations. The high amount of HP-β-CD required in this composition also 
makes it expensive. A possible solution that is currently being studied is the spray-drying 
of lorazepam-cyclodextrin 1:1 complexes, to provide a dry, and thus stable, semi-finished 
product, which can be compounded by pharmacist for individual patients.
Besides the technical challenges, there are also uncertainties around the safety of 
cyclodextrins in children below the age of 2 years. The oral bioavailability of HP-β-CD  very 
low, and high doses could cause reversible diarrhoea. For children below the age of 2 
years, the currently suggested permitted daily exposure of HP-β-CD is set at 16 mg/kg/day 
for oral ingestion (12). This is set at one tenth of the adult value, as there are insufficient 
data in this age group. It corresponds with a maximum allowable lorazepam intake of 
0.16 mg/kg/day, which may be surpassed in clinical practice. In summary, a cyclodextrin 
formulation is a feasible option, but would require considerable additional research.
Our efforts to create a micellar solution of lorazepam resulted in a physically and chemically 
stable product, and the high amounts of surfactants required to obtain a stable solution 
would not exceed the Acceptable Daily Intake (ADI) limits for food additives set by the 
WHO (15, 16). However, the taste of the formulation made it unacceptable for use in 
children. The development of this formulation was therefore discontinued. 
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With regard to the palatability assessment by healthy volunteers, it is known that children 
experience different taste sensations than adults (17). In this stage of development we 
considered a first screening by an adult tasting panel acceptable. A palatability assessment 
is included in the clinical trial that is currently performed with our formulation in paediatric 
ICU patients. 
In conclusion, we have studied different options for an oral solution of a poorly water soluble 
drug, using lorazepam a model drug. The organic solvent based formulation showed 
adequate stability, taste and dosing flexibility, rendering it suitable for the paediatric 
population above the age of one month. Our final, organic solvent-based formulation is 
currently used in a paediatric clinical trial to study the oral pharmacokinetics of lorazepam 
in PICU patients from the age of 1 month to 12 years old. This formulation is preferable 
to manipulation of commercial dosage forms and non-standardized extemporaneously 
compounded formulations, and may serve as an example for the development of 
comparable drug substances into oral liquid formulations. 
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ABSTRACT
Objective
Amlodipine, a long-acting dihydropyridine calcium channel blocker, is frequently 
prescribed to pediatric patients. To date, no suitable pediatric formulation has been 
available. In this study, an amlodipine oral solution was developed and tested for 
bioequivalence to tablets in healthy adult volunteers. 
Methods
This study was designed as an open-label, single-dose, two-sequence, two-period, 
crossover trial to assess the bioequivalence of a newly developed  amlodipine besylate 
oral solution 0,5 mg/mL compared to Norvasc® 5 mg tablets. Thirteen adult subjects 
(mean [standard deviation] age of 23.2 [3.6] years, weight 71.5 [7.7] kg) were included and 
blood samples were collected for 72 hours. Amlodipine plasma levels were determined 
using a validated UPLC-MS/MS assay. Non-compartmental pharmacokinetic parameters 
were compared between the formulations according to European Medicines Agency 
(EMA) bioequivalence guidelines.
Results
The 90% confidence intervals of the test/reference ratios of the geometric means for the 
primary pharmacokinetic parameters AUC0-72 (88.24 - 104.37%) and Cmax (99.00 - 121.40%) 
were within the acceptance range of 80.00-125.00% for bioequivalence. Mean (SD) 
AUC0-72 was 102.7 (26.8) µg*h/L for the solution and 108.2 (30.6) µg*h/L for the tablet. 
Mean (SD) Cmax of the solution was 3.11(1.06) µg/L with a median (IQR) Tmax of 4.0 (2.6-7.5) 
hours. Mean (SD) Cmax of the tablet was 2.91 (0.84) µg/L with a median (IQR) Tmax of 6.0 (4.0-
14.0) hours. Intrasubject coefficients of variation were 10.2% (AUC0-72 ) and 12.4% (Cmax).
Conclusions
The formulations are bioequivalent according to EMA guidelines. This warrants further 
study of our novel amlodipine oral solution in pediatric patients.
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INTRODUCTION
Amlodipine is a long-acting dihydropyridine calcium channel blocker widely used in both 
adults and children. Currently, it is one of the antihypertensive agents recommended by 
the European Society of Hypertension for the management of hypertension in children 
and adolescents (1). Within the group of calcium channel blocking agents, amlodipine 
is considered first choice treatment for chronic hypertension in children, based upon its 
pharmacological characteristics and as the most extensively studied drug within this class 
(2). Its main advantage is its long half-life, enabling once or twice daily administration.
Amlodipine is officially licensed for treatment of children from the age of six, but also 
prescribed off-label to children from the age of 1 month in a dose of 0.06-0.3mg/kg per 
day (1). However, the commercial available formulations are limited to tablets of 5 or 10 
mg. These tablets are not suitable for the youngest age group, in which lower dosages 
and higher dose flexibility are generally needed. A liquid formulation would therefore be a 
more appropriate dosage form for young patients. Some liquid formulations of amlodipine 
have been proposed, but have been composed as suspensions (3-5). For a drug that can 
be highly toxic when overdosed, especially in children (6), a suspension is not preferred. 
Suspensions can become inhomogeneous, leading to accidental administration of wrong 
dosages. For this reason we developed a solution of amlodipine, for oral pediatric use. We 
validated its stability and the formulation has shown to be stable for at least one year (7). 
Amlodipine immediate release, solid dosage forms of ≤5 milligrams are classified in 
Biopharmaceutics Classification System class I by the WHO (8). This implies a high gastro-
intestinal solubility and permeability of amlodipine. Given these characteristics, we 
expect our oral solution to be bioequivalent to amlodipine tablets according to European 
Medicines Agency (EMA) guidelines (9). However, with the test product being a solution, 
a shift in Tmax might occur. To be able to safely apply the oral solution in the pediatric 
population, we chose to first elucidate the pharmacokinetic parameters of the oral liquid 
in adult volunteers. 
In adults, amlodipine is slowly and completely absorbed after oral ingestion with peak 
plasma concentrations between 3 and 12 hours (10-12). As a result of its first-pass effect, 
tablets show high, but variable, bioavailability (50-90%), which is not influenced by food 
(10, 12, 13). Amlodipine is extensively metabolized in the liver, mainly by CYP3A4 (12). 
Initial metabolism involves the oxidation of the dihydropyridine ring to the pyridine 
analogue, complemented by side-chain oxidation and hydrolysis of one or both side-
chain ester groups. Around 60% of amlodipine is excreted in the urine, with up to 5% in 
unchanged form (14). The half-life ranges between 30 and 50 hours, and seems to increase 
with age (10, 14).
In this study we investigate the bioequivalence of 10 mL amlodipine besylate 0.5 mg/
mL in comparison with the innovator 5 mg Norvasc® (amlodipine besylate) tablet after a 
single oral dose in healthy volunteers, in a crossover design.
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METHODS
Drug formulations
The quantitative composition of the amlodipine oral solution is shown in Table 7.1. Long-
term stability studies have proven that the solution is stable for at least one year when 
stored at 4°C, with the contents of amlodipine besylate not dropping below 95% and 
related substances remaining below 0.4%. The reference treatment consisted of Norvasc® 
(Pfizer BV, Capelle a/d Ijssel, The Netherlands) 5 mg tablets, containing the excipients 
sodium starch glycollate (type A), calcium hydrogen phosphate, anhydrous, cellulose, 
microcrystalline and magnesium stearate.  
Table 7.1 Composition of the test formulation amlodipine besylate oral liquid 0.5 mg/mL.
Composition of amlodipine oral liquid Quantity
Amlodipine besylate 69.0 mg
Methyl paraben solution* 15% m/v  FNA 304 mg 
Sucrose syrup^ 8.53 g
Purified water Ad 100 mL
FNA Formulary of Dutch Pharmacists; * solution of methyl paraben in propylene glycol 
^solution of 630 mg sucrose and 1 mg methyl parahydroxybenzoate in 1 g of water
Study population and Recruitment
From March to May 2013, we recruited healthy male and female volunteers in Rotterdam, 
The Netherlands. Subjects were eligible for inclusion if they met the following criteria: 
age between 18 and 55 years, Caucasian and body mass index from 19 to 25. All subjects 
were considered healthy on the basis of a physical examination and recording of medical 
history performed by a physician. Exclusion criteria for participation were: sitting blood 
pressure lower than 120 mmHg systolic and 80 mmHg diastolic in resting conditions, use 
of any other medication excluding contraceptives, smoking, pregnancy, history of alcohol 
or drug abuse, known hypersensitivity to dihydropyridine derivatives or any other contra-
indication for amlodipine use.
The study was conducted in line with Good Clinical Practice and the Declaration of 
Helsinki and approved by the Medical Ethics Committee of the Erasmus Medical Centre 
and by the Dutch competent authority. Written informed consent was obtained from each 
subject. All subjects had the right to withdraw from the study at any time without any 
consequences. The trial was registered in the Dutch Trial Register.
Study design
The study was conducted in a single-center, randomized, open-label, two-sequence, two-
period, crossover design at the Erasmus Medical Centre, Rotterdam, The Netherlands. We 
evaluated two single-dose treatments of amlodipine. Two sequences (test-reference and 
reference-test) were randomly allocated to subjects using the Trial Online Process (TOP) 
program of the HOVON data center, Rotterdam, The Netherlands. Administration of the 
study drug was not blinded, because of the difference of appearance of tablets and liquid 
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and because it was not deemed necessary for the purpose of the study. 
A wash-out period of at least 14 days was maintained between test and reference 
treatment. An intravenous catheter was placed on the day of study drug administration 
to draw blood samples. Samples were taken at baseline and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 
10, 12 , 14, 24, 48 and 72 hours post dose. The samples at 24, 48 and 72 were drawn by 
venipuncture. The test product, 10 mL of amlodipine oral liquid 0,5 mg/mL, was dispensed 
in an oral syringe and ingested without additional fluid, to enable a taste assessment. 
The reference product (tablet) was ingested with tap water. The subjects underwent an 
overnight fast for at least eight hours. Water and tea were allowed before and during the 
study period. Standardized meals were provided at 1, 5 and 11 hours after administration 
of the study drug. Consumption of grapefruit juice and smoking was not allowed during 
the study. 
For safety reasons, we monitored sitting blood pressure and heart rate of all subjects at 
baseline and 1, 3, 6, 8, 10, 12, 14, 24 48 and 72 hours post dose for both study drugs using 
an automated oscillometric device. Subjects were excluded if their systolic blood pressure 
dropped below 70 mmHg or if their diastolic blood pressure dropped below 40 mmHg. 
After administration of the test product, the subjects had to fill out a taste assessment 
form based on a five-point hedonic scale. We surveyed the subjects for adverse events 
during the study period and one week after.  
Amlodipine analysis
Plasma concentrations of amlodipine were determined using a validated ultra-
performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method, 
that was developed for the purpose of this clinical study. 
Plasma samples were stored at -80°C until analysis.  After thawing at room temperature, 
protein was precipitated by adding 600µl methanol, containing the internal standard 
(amlodipine-d4, Art Molecule, Poitiers, France), to 200µl plasma sample. After vortexing 
for ten seconds, samples were centrifuged at 15973 g for five minutes. After centrifugation 
600µl supernatant was diluted with 150µl of methanol: water (50:50 v/v) and vortexed 
for 5 seconds. Samples were kept at room temperature until analysis. A 5-µl sample was 
injected onto the UPLC-MS/MS system (Thermo Scientific Dionex Ultimate 3000) consisting 
of an Ultimate 3000 RS quaternary UHPLC-pump, an Ultimate 3000 RS auto sampler and 
an Ultimate 3000 RS column compartment in combination with a Thermo Scientific TSQ 
vantage MS/MS for mass spectrometric detection. The auto sampler was kept at  15°C. 
Isocratic elution was achieved with a mixture of 65% of  2mM Ammoniumacetate + 0,1% 
formic acid in water (mobile phase A) and 35% of 2mM Ammoniumacetate + 0,1% formic 
acid in methanol (mobile phase B) at a flow rate of 0,4 ml/min. The column (Waters Acquity 
UPLC HSS T3, 2.1x100 mm, 1.8 µm) temperature was set at 40°C. The total runtime was 
4 minutes. Compounds were detected using Electron Spray Ionization (ESI) in positive 
mode. The SRM transitions of Amlodipine and Amlodipine-d4 were 409 > 238 and 413 
> 238 [M+H]+ respectively. Optimal MS settings were as follows: Spray Voltage 3000V, 
Capillary Temp 200°C, Vaporizer Temp. 400°C, collision gas pressure 1,5 mTorr, Sheat gas 
50, Ion Sweep gas 5, Aux gas 20, Collision Energy 10V and S-lens RF amplitude 64. Data 
processing was performed with LcQuan 2.7 software (Thermo Scientific).
Satisfying results of intraday precision, interday precision and accuracy were conclusively 
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demonstrated during the period of method validation. Six replicates of three levels of 
quality control (QC) samples (0.493, 7.398 and 16.77 µg/L) were used to determine 
accuracy and intraday precision with the maximum coefficient of variation (%CV) set at 
15 %. For interday precision three levels of QC samples (0.493, 7,398 and 16.77 µg/l) were 
analyzed in duplicate on six consecutive days. The maximum %CV was also set at 15%. 
The linear calibration curves were obtained in the concentration range of 0.2 to 20 µg/L 
using a weighing factor of 1/x. The correlation coefficient was 0.9965. The lower limit of 
quantification was 0.1 µg/L. 
Pharmacokinetic and statistical evaluation
The intra-subject coefficient of variation (CV) for pharmacokinetic parameters was assumed 
to be 16% (4) and the geometric mean ratio (test/reference) of the pharmacokinetic 
parameters was assumed to be 1.05. We expected the minimum sample size of 12 evaluable 
subjects to be sufficient to reject the null hypothesis “lack of bioequivalence between test 
and reference treatment” with α = 0,05 and a power of at least 80% (15). We performed 
the statistical analysis according to recommendations of the European Medicines Agency 
on the investigation of bioequivalence (9). The assessment of bioequivalence was based 
upon 90% confidence intervals for the ratio of the population geometric means of the 
test and reference formulation for the parameters AUC0-72 and Cmax, equivalent to two one-
sided tests with the null hypothesis of bioinequivalence at the 5% significance level. AUC0-
72 was considered adequate for comparison of extent of exposure of the two immediate 
release formulations, as the absorption phase of amlodipine has been covered. We 
calculated the AUC0-72 using the linear trapezoidal rule. Extrapolation to infinity (AUC0-∞) 
was performed by dividing the last measurable serum concentration by the elimination 
rate constant (λz). ANOVA was carried out using the respective log-transformed data. The 
mean square error of ANOVA was used as a variance estimate to calculate the 90% CI. The 
predefined acceptance range was 80.00% to 125.00% for AUC0-72  and Cmax. The elimination 
half-life was determined from 0.693/λz. We estimated Cmax values and Tmax directly from 
the observed plasma concentration–time data. The software used for all calculations was 
Microsoft Excel 2010 (Microsoft Corporation, Seattle, Washington), IBM SPSS Statistics 
21.0.0.1 (IBM Corporation, Armonk, New York) and WinNonlin 6.01 (Pharsight Corporation, 
Palo Alto, California).
RESULTS
A total of 13  subjects were enrolled in the study (4 male, 9 female, mean [SD] age of 23.2 
[3.6] years; weight 71.5 [7.7] kg; height 177.5 [8.5] cm). One subject dropped out during 
study period 2, due to displacement of the intravenous catheter. After t=1.5 no evaluable 
blood samples were obtained and subsequently this subject was excluded from the 
pharmacokinetic analysis. 
No serious adverse events occurred during the study period. The blood pressures 
remained above the threshold for exclusion in all subjects. One subject complained of 
headache in the week after the second treatment period, but this was not attributed to 
the study medication. Another subject suffered from the flu between treatment periods 
but was considered healthy at the start of the second study period. 
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Pharmacokinetics
The liquid test and the solid reference preparation showed similar pharmacokinetic 
properties. Figure 7.1 shows the mean amlodipine concentration versus time plots. 
Individual amlodipine concentration versus time plots are shown in Figure 7.2. No relevant 
pre-dose amlodipine concentrations were observed. An overview of the pharmacokinetic 
parameters of the two amlodipine dosage forms is given in table 7.2. Mean (SD) AUC0-
72 was 102.7 (26.8) µg*h/L for the test product and 108.2 (30.6) µg*h/L for the reference 
product. Mean (SD) AUC0-∞ was extrapolated to 141.3 (50.3) µg*h/L for the test product and 
147.4 (49.6) µg*h/L for the reference product. Mean (SD) Cmax of the test product was 3.11 
(1.06) µg/L with a median (IQR) Tmax of 4.0 (2.6-7.5) hours. Mean (SD) Cmax of the reference 
product was 2.91 (0.84) µg/L with a median (IQR) Tmax of 6.0 (4.0-14.0) hours. Intrasubject 
coefficients of variation (derived from the mean square error of the ANOVA) were 10.2% 
(AUC0-72 ) and 12.4% (Cmax). A non-parametric Wilcoxon signed rank test demonstrated a 
significant difference in Tmax (p=0,007). 
Table 7.2 Pharmacokinetic parameters for amlodipine test (liquid) and reference (tablet) 
formulations after administration of a single 5-mg dose in 12 healthy adult volunteers.
Test (liquid) Reference (tablet)
tmax (h)
Median (IQR) 4.0 (2.6-7.5) 6.0 (4.0-14.0) 
Range 2.00 - 10.0 2.50 - 23.8
Cmax (µg/L)
Mean (SD) 3.11 (1.06) 2.91 (0.84)
Geometric mean (Geometric CV) 2.97 (30.8%) 2.80 (30.4%)
Range 2.07 - 5.83 1.80 - 4.54
AUC0-72 (µg*h/L)
Mean (SD) 102.7 (26.8) 108.2 (30.6)
Geometric mean (Geometric CV) 99.4 (27.7%) 104.2 (29.8%)
Range 57.83 - 141.44 60.94 - 168.10
AUC0-∞ (µg*h/L)
Mean (SD) 141.3 (50.3) 147.4 (49.6)
Geometric mean (Geometric CV) 133.7 (36.0%) 139.8 (35.3%)
Range 66.49 - 260.42 74.57 - 237.66
t1/2 (h)
Mean (SD) 36.2 (10.9) 36.4 (8.95)
Range 25.2 - 66.1 25.2 - 52.6
tmax = time to reach Cmax; Cmax = maximum plasma concentration; AUC0-72 = area under the 
concentration-time curve from time zero to 72 hours; AUC0-∞ = AUC from time zero to infinity; t1/2 = 
terminal elimination half-life
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Bioequivalence
The 90% confidence intervals of the test/reference ratios of the geometric means for the 
primary pharmacokinetic parameters AUC0-72 (88.24 - 104.37%) and Cmax (99.00 - 121.40%) 
are within the acceptance range of 80.00-125.00% for bioequivalence, showing that the 
liquid is bioequivalent to the tablet.  
Figure 7.1 Composite (mean±SD) plasma concentration versus time curves after administration of 
a single 5-mg dose the test (liquid) and reference (tablet) formulations in healthy adult volunteers.
Taste assessment
The average first impression of the taste of the oral solution was rated between ‘not good, 
not bad’ and ‘good’ (mean 2.75 on 5 point scale where 1= very good and 5= very bad), with 
two subjects rating it as ‘bad’. Two minutes after ingestion the taste of the oral solution 
was on average rated as ‘good’ (mean 2.17). Subjects described the taste as a combination 
Figure 7.2 Individual amlodipine plasma concentration versus time plots of the liquid test 
formulation and the solid reference formulation. 
113Amlodipine bioequivalence
of sweet and bitter. All of the subjects would take the oral solution again, if necessary. 
Only one subject would not recommend it to other people. 
DISCUSSION
In this study a novel liquid formulation of amlodipine besylate was tested for 
bioequivalence to the reference Norvasc® tablet. The 90% confidence intervals of the 
ratios of the geometric means for the primary endpoints AUC0-72 and Cmax were well within 
the pre-defined bioequivalence acceptance range of 80.00-125.00%. This means that the 
two formulations are bioequivalent according to EMA guidelines. 
PK parameters for both formulations were similar, except for the anticipated shorter Tmax 
observed for the liquid formulation. Since amlodipine is absorbed relatively slowly and 
no significant change in peak concentration occurs, this difference is deemed acceptable. 
The PK parameters were likewise comparable to previously published bioequivalence 
studies using Norvasc® 5 mg (AUC0-∞ mean 166.3, SD 76.7 µg*h/L (16) and AUC0-∞ mean 
203.2, SD 52.1 µg*h/L (17)). The mean elimination half-life of 36 hours and its marked 
between subject variability found in this study are consistent with previous studies in 
young, healthy volunteers (10-12, 16, 18, 19). The individual half-lives in this study ranged 
between 25 and 66 hours, but the wash-out period between treatments was sufficiently 
large to achieve more than six half-lives for all subjects.
In both the mean concentration-time plots (Figure 7.1) and multiple individual 
concentration-time plots (Figure 7.2), a second peak was observed around t=12 
hours. Other pharmacokinetic studies on amlodipine (10-13, 16, 18), did not show this 
profile, possibly due to more sparse blood sampling around that time point. However, 
in accordance with our results, a similar profile with a secondary peak was found in a 
study on the influence of gastrointestinal transit times on the AUC of several calcium 
antagonists, including amlodipine (20). It has been suggested that amlodipine undergoes 
enterohepatic circulation (21), which is supported by the excretion of metabolites in the 
feces (14). A possible explanation of the second peak could be re-entering of  amlodipine 
in  the intestinal tract with the excretion of bile during/after the evening meal. 
Although the EMA guideline for the investigation of bioequivalence (9) recommends 
no intake of food for at least four hours post-dose, we limited the fasting period to one 
hour after the administration of the study drug, based upon several studies showing no 
direct influence of food on the absorption of amlodipine (22, 23). Likewise there was no 
restriction on water and tea intake as the dissolution of amlodipine from the dosage form 
is unlikely to effect the absorption (10, 21).  
For small molecules, the EMA considers bioequivalence studies in healthy volunteers 
to be adequate to detect formulation differences and to allow for extrapolation of the 
results to populations for which the reference medicinal product is approved (9).  It is 
generally accepted that gastro-intestinal permeability in children above the age of 2 
years is equivalent to that observed in adults (24). For in vivo solubility however, there is 
debate as to whether results from bioequivalence studies can be directly extrapolated to 
pediatric patients (25), because of the relatively smaller volume of gastro-intestinal fluid in 
children. It is therefore desirable to further elucidate the pharmacokinetic performance of 
the amlodipine oral solution in the pediatric population. The results of this study will form 
the basis for a study protocol in children. 
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CONCLUSION
In conclusion, in this study we showed bioequivalence of the newly developed amlodipine 
oral solution compared to Norvasc® 5 mg tablets. With these results, the use of the liquid 
in the intended target population, children with chronic hypertension, can be safely 
explored in future studies.  
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ABSTRACT 
Aim 
Intravenous sedatives used in the paediatric intensive care unit (PICU) need to be tapered 
after prolonged use to prevent iatrogenic withdrawal syndrome (IWS). We evaluated the 
occurrence of IWS and the levels of sedation before and after conversion from intravenous 
midazolam to oral lorazepam.
Methods 
This was a retrospective, observational, single cohort study of children under the age of 
18 admitted to the PICU of the Erasmus MC-Sophia Children’s Hospital, Rotterdam, The 
Netherlands, between January 2013 and December 2014. The outcome parameters were 
the Sophia Observation withdrawal Symptoms (SOS) scale scores and COMFORT Behavior 
scale scores before and after conversion.
Results 
Of the 79 patients who were weaned, 32 and 39 had before and after SOS scores and 
77 had COMFORT scores. IWS was reported in 15/79 patients (19.0%) during the 48 
hours before the start of lorazepam and 17/79 patients (21.5%) during the 48 hours after 
treatment started. Oversedation was seen in 16/79 patients (20.3%) during the 24 hours 
before substitution and in 30/79 patients (38.0%) during the 24 hours after substitution.
Conclusion 
The weaning protocol was not able to prevent IWS in all patients, but converting from 
intravenous midazolam to oral lorazepam did not increase the incidence.
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INTRODUCTION
Most children admitted to a paediatric intensive care unit (PICU) receive intravenous 
sedatives and analgesics to relieve anxiety, distress and pain and to tolerate mechanical 
ventilation and other PICU-related procedures. The most commonly used sedatives and 
analgesics in paediatrics are midazolam and opioids (1). Unfortunately, these drugs can 
cause iatrogenic withdrawal syndrome (IWS) after prolonged use (2). 
To prevent IWS, a protocolled approach to taper the drugs and to regularly monitor 
withdrawal symptoms and sedation levels is recommended. Intravenously administered 
medication can be switched to oral dosage forms, to facilitate gradual weaning without 
the need for cardiorespiratory monitoring required for intravenous sedation, and to omit 
the need for intravenous access. Treatment can then be continued outside the PICU 
and removing intravenous access lowers the risk of infection. Oral lorazepam has a long 
half-life in children, with a median of 17 hours (range 8-53 hours), which prevents large 
fluctuations in plasma concentrations, and also has a lack of active metabolites. That is 
why it is often used off-label as a substitute for intravenous midazolam (2-4). 
In our local weaning protocol, the calculation of the initial dose of oral lorazepam was based 
on a conversion factor proposed by Tobias et al (5), which assumed that lorazepam was 
twice as potent as midazolam and had a six-time longer half-life, based on adult data. This 
lorazepam starting dose is calculated irrespective of the potential impact of maturation 
of lorazepam and midazolam metabolism due to age or other factors influencing drug 
exposure, such as critical illness. In addition to this, the bioavailability of oral lorazepam 
in children is unknown and, therefore, no correction is possible for a potential incomplete 
bioavailability. In summary, this means that the current dosage of lorazepam for weaning 
of midazolam may not be optimal. At the time of our study, no clinical data on the 
conversion from midazolam to lorazepam in PICU settings was available in the literature. 
Due to this limited information, the aim of this study was to evaluate the occurrence of IWS 
and the level of sedation before and after conversion from intravenous midazolam to oral 
lorazepam. We also wanted to assess the safety of our current midazolam to lorazepam 
conversion protocol.
METHODS
Design and study population 
A retrospective, single centre, cohort study was performed to evaluate the move from 
intravenous midazolam to oral lorazepam to keep patients comfortable and prevent IWS. 
Our study population was admitted to the level five PICU of the Erasmus MC - Sophia 
Children’s Hospital, Rotterdam, The Netherlands, between January 2013 and December 
2014. Patients were selected from our Critical Care Suite electronic patient data 
management system (Picis Clinical Solutions SA, Barcelona, Spain), when they had received 
oral lorazepam following intravenous midazolam. The exclusion criteria were the use of 
midazolam and lorazepam for epilepsy or delirium, when the latter had been diagnosed 
by a trained psychiatrist, or for other reasons such as incidental sleep medication. The 
medical ethics committee of the hospital waived the need for institutional review board 
approval and informed consent according to the Dutch law on Medical Human Research.
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IWS and sedation scores 
To achieve optimal weaning, it is necessary to monitor symptoms of IWS from 
benzodiazepines and opioids and to monitor the level of sedation. These are assessed 
using the Sophia Observation withdrawal Symptoms (SOS) scale to determine IWS and the 
COMFORT behavior (COMFORT-B) scale to assess the level of sedation (6-8). The SOS scale 
consists of 15 items representing signs and symptoms of opioid and, or, benzodiazepine 
withdrawal, including changes in heart and respiratory rate and signs of discomfort. IWS 
scoring is initiated at start of weaning and performed at eight-hour intervals, when the 
occurrence of IWS is suspected, and to evaluate any interventions that were made to treat 
IWS. The COMFORT-B scale consists of six behavioural items and is applied in combination 
with the Nurses Interpretation of Sedation Score (NISS) (6) from the start of mechanical 
ventilation. It has been validated to assess the level of sedation in ventilated and non-
ventilated children. Scoring is performed by the attending nurses at eight-hour intervals 
and if there are signs of distress or increasing discomfort. It continues until discharge from 
the PICU or until all sedative medication has been stopped. 
Weaning protocol 
Weaning of sedative and analgesic medication is initiated as soon as the patient’s 
underlying condition and pathology improves, their electrolytes are within normal range 
and they are cardiovascularly stable. The protocol for weaning of continuous opioids and 
sedatives implemented at our PICU starts with decreasing continuous infusion rates of 
the drugs and the intervals depend on the preceding length of treatment. Infusion rates 
are decreased, one drug at a time, by 10% of the initial rate. This occurs every 24 hours 
when the patient has received the drug for 6-9 days and every 48 hours when they have 
received the drug for 10 days or more. The intravenous medication is converted to an 
effect-equivalent dose of oral medication within the same therapeutic class when the 
patient is due to be discharged to the general ward without cardiorespiratory monitoring, 
when intravenous access is no longer required or available or when prolonged weaning is 
expected. The initial daily dose of oral lorazepam is calculated by dividing the daily dose of 
midazolam by 12. This conversion is based on the lorazepam and midazolam ratio for half-
life (6:1) and its relative potency (2:1) in adults (5). This lorazepam dose is administered 
orally four times a day and the intravenous midazolam is tapered over 24 hours as shown 
in Figure 9.1. Lorazepam is subsequently tapered in steps of 10% of the initial dose every 
24 or 48 hours. If there are withdrawal symptoms, indicated by an SOS score of four or 
more, a rescue dose of 0.1 mg/kg midazolam is administered or the oral lorazepam dose 
is increased to the previous strength. If applicable, opioids and other sedatives, such as 
morphine, fentanyl, clonidine and pentobarbital, are also converted to oral alternatives in 
a similar manner, for example methadone, clonidine per os and phenobarbital, preferably 
with a minimum of 48 hours between conversions. They are tapered according to the 
same principles.
Medication
Intravenous midazolam was administered using a Perfusor FM syringe pump (B Braun 
Medical, Oss, The Netherlands), in concentrations of 1 mg/ml or 5 mg/ml dissolved in 5% 
glucose, which were prepared by the pharmacy. Oral midazolam for rescue administrations 
was available as an extemporaneous liquid of 1 mg/ml. Oral lorazepam was administered 
as either commercial tablets, extemporaneous capsules of 0.1 mg or a 4 mg/ml commercial 
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injection fluid that was administered orally. Solid dosage forms were usually dispersed in 
water and administered through a feeding tube. 
Figure 9.1 Tapering of midazolam after substitution with oral lorazepam. The intravenous 
midazolam dose is halved after the second administration of lorazepam, again halved after the 3rd 
administration of lorazepam and ceased after the 4th administration of lorazepam (24h after switch). 
The first dose of lorazepam is calculated upon the last infusion rate of midazolam.
Data collection 
Data were extracted from the electronic medical records. The clinical and demographic 
parameters that were retrieved included age, sex, diagnosis, cumulative doses and 
duration of midazolam and lorazepam therapy, analgesic and sedative co-medication and 
the patient’s destination after their discharge from the PICU. 
Outcomes 
The SOS scores were retrieved to determine the incidence of withdrawal from 48 hours 
before substitution to 48 hours after substitution. A cut-off score of at least four was 
defined as withdrawal. The COMFORT-B scores and NISS scores were analysed from 48 
hours before substitution to 48 hours after substitution to determine the level of sedation. 
COMFORT-B scores of  ≥23 or 11-22 with a NISS of one were regarded as undersedation, 
COMFORT-B scores of 11-22 with a NISS of two were regarded as adequate sedation and 
COMFORT-B scores of ≤10 or 11-22 with a NISS of three were regarded as oversedation. 
Similarly, the number of rescue dosages of midazolam and other sedatives were compared 
from 48 hours before to 48 hours after substitution. The frequency and severity of apnoeas 
and the need for flumazenil during the 48 hours after start of lorazepam were used to 
assess the safety of the conversion. Apnoeas were registered manually in the patient 
data management system by the attending physician or nurse as part of standard care. 
The agreement of the actual midazolam to lorazepam conversion with the conversion 
protocol was assessed with respect to the dose calculation of lorazepam and the tapering 
of midazolam within 24 hours after conversion. 
Analysis 
Data were analysed using IBM SPSS statistics version 21.0 (IBM Corporation, New York, 
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USA). Demographic and clinical data were processed using descriptive statistics. The 
number of rescue administrations of midazolam and other sedatives before and after 
substitution were compared using a paired-sample t-test. 
RESULTS
During the 24-month study period between January 2013 and December 2014, 111 cases 
met the inclusion criterion for oral lorazepam use after intravenous midazolam therapy. 
After excluding three patients who started lorazepam in 2012, 20 patients who received 
lorazepam for other purposes than weaning, and excluding multiple occasions within one 
subject (n=9), 79 cases were included for further analysis. The patient characteristics are 
listed in Table 9.1. 
Table 9.1 Patient characteristics (n=79).
Parameter
Sex: 
 Male 
 Female
n 
37 
42
% 
46.8 
53.2
Age median (months) (IQR) 5.3 (1.7-19.8)
Age: 
 0-27 days 
 28 days -11 months 
 12- 23 months 
 2-11 years 
 12-18 years
n 
13 
40 
8 
16 
2
% 
16.5 
50.6 
10.1 
20.2 
2.5
Weight median (kg) (IQR) 5.5 (3.6-10.0)
Reason for PICU admission: 
 Cardiac 
 Non-cardiac surgical 
 Neurological 
 Infection/respiratory 
 Trauma 
 Congenital 
 Other
n 
30 
4 
1 
19 
2 
9 
14
% 
28.0 
5.1 
1.3 
24.1 
2.5 
11.4 
17.7
 Ventilation  
ECMO therapy
79 
7
100 
8.9
Transfer after PICU: 
 Home 
 Other hospital 
 Other department 
 Mortality
n 
7 
18 
45 
9
% 
8.9 
22.8 
57.0 
11.4
Median length of PICU stay  
 Days (range)
 
32 (4-183)
ECMO = extracorporeal membrane oxygenation; IQR = inter quartile range; PICU = paediatric 
intensive care unit
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At the point of the midazolam to lorazepam switch, the median duration of midazolam 
infusion, from the day of admittance to the Sophia Children’s Hospital, was 12 days (range 
1-69) and the median cumulative dose was 46.5 mg/kg (range 0.47-287). We also noted 
that 23 patients were still on invasive ventilation and 11 patients had received midazolam 
at infusion rates that were higher than 0.35 mg/kg/h during their admission. Further 
information on the patients’ sedative treatment during PICU admission is summarised in 
Table 9.2. 
Table 9.2 Sedative treatment characteristics during PICU admission (n=79).
Parameter Median (range) unit
Median dose per patient: 
Midazolama 
Lorazepamb
130 (30-393) 
0.30 (0.08-2.76)
mcg/kg/h 
mg/kg/d
Cumulative dose: 
Midazolamc 
Lorazepam
46.5 (0.47-287) 
1.42 (0.08-79.32)
mg/kg 
mg/kg
Maximum infusion rate before subsitution: 
Midazolam 300 (12-1000) mcg/kg/h
Duration of infusion until substitution:  
Midazolam 12 (1-69)           days
Duration of midazolam therapy until substitutiond n         %
< 5 days 
5-10 days 
> 10 days
3             
16                 
60
3.8 
20.3 
75.9
Duration of lorazepam taper: Days (range)
Lorazepame 22 (3-97) (n=45)
Fixed-interval and continuous sedative and analgesic 
co-medication:
n % 
Alimemazine po 
Clonidine 
  iv 
 po 
Esketamine iv 
Fentanyl iv 
Methadone po 
Morphine iv 
Pentobarbital iv 
Propofol iv
10 
 
41 
23 
26 
9 
16 
73 
3 
19
13 
 
52 
29 
33 
11 
20 
92 
4 
24
a Throughout PICU admission, b Starting dose at substitution, c Until substitution, d Midazolam 
therapy was calculated from the first administration to the last administration in the Sophia 
Children’s hospital. The short administration of one day is due to the transfer from another 
hospital.  e n=45. Total lorazepam duration, including use at home. Only the patients with complete 
post clinical duration were used to calculate the median. 
po = orally; iv = intravenous; PICU = paediatric intensive care unit.
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The SOS scores were available for 32/79 (40.5%) of the patients in the 48 hours before 
substitution and 39/79 (49.4%) of the patients in the 48 hours after substitution. The 
median score per patient before the start of lorazepam ranged between 0-9.0, with 15 
patients (19.0%) having one or more SOS score of at least four, indicating IWS. After the 
start of lorazepam the median score per patient ranged between 0-5.0, with 17 patients 
(21.5%) having one or more SOS score of at least four. In eight of these 17 patients, the 
morphine infusion rates were decreased during the 96 hours around conversion. Figure 
9.2 shows the range of the highest SOS score per patient within our study period. Seven 
patients experienced IWS both before and after substitution and 11 patients experienced 
both oversedation and IWS in the 48 hours after substitution. 
Figure 9.2 Distribution of the highest SOS score per patient during the first 48 hours before 
substitution (grey bars) and 48 hours after substation (open bars) of iv midazolam with oral 
lorazepam. Maximum score is 15, with scores ≥ 4 indicating withdrawal.
COMFORT-B scores were available for 77/79 patients (97.5%). All the available scores are 
shown in Figure 9.3, with a median of three scores per patient per day. From a total of 1,122 
COMFORT-B scores, 136 incidences of oversedation and 150 incidences of undersedation 
were determined, in combination with the NISS, during the 96-hour study period. Only 44 
of the incidences of undersedation were accounted for by COMFORT-B scores of at least 
23 and the other 106 by a COMFORT-B score between 11-22 and a NISS of one.
In some patients the COMFORT-B scores, in combination with the NISS, were outside the 
adequate sedation range and these are presented in Figure 9.4. This figure shows that 
the incidence of oversedation increased after substitution with lorazepam. During the 
two days before substitution, 13 and 16 patients, respectively, experienced oversedation 
compared to 39 and 30 patients in the two days after substitution. Undersedation 
decreased from 28 and 21 patients before lorazepam initiation to 16 and 13 patients after 
the start of lorazepam. 
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Figure 9.3 Histograms of available COMFORT-B scores during the four different study periods. The 
window between the dotted lines show scores that are regarded as adequate sedation, while lower 
scores (≤10) are regarded as oversedation and higher scores (≥23) as undersedation.
A total of 34 patients (43.0%) received one or more rescue administrations of midazolam 
before substitution, compared to 19 patients (24.1%) after substitution, with a 95% 
confidence interval (95% CI) of  -0.06-0.77, p=0.096. Furthermore, 29 patients (36.7%) 
received rescue administrations of other sedatives before substitution compared to 
21 patients (26.6%) after substitution (95% CI -0.18-0.94, p=0.178). In total, 50 patients 
(63.3%) received rescue administrations before substitution and 34 patients (43.0%) after 
substitution with a median of two administrations in both periods. During the 48-hour 
post substitution period, 56 patients (70.9%) continued their sedative or analgesic co-
medication. Co-medication was decreased in 44 patients and increased in three patients.
Regarding the safety of the substitution, no apnoeas were reported and no flumazenil was 
prescribed during the 96 hours around the conversion. 
142 Chapter 9
Figure 9.4 Oversedation: COMFORT-B scores ≤10 or 11-22 with NISS=3. Adequate sedation: 
COMFORT-B scores of 11-22 with NISS =2. Undersedation: COMFORT-B scores ≥23 or 11-22 with 
NISS =1. For study periods 1-4 respectively 7, 9, 11 and 6 children were both under- and oversedated.
Adherence to the conversion protocol was variable. The median midazolam/lorazepam 
dose ratio was 11.4 (range 1.31-22.6) and 62.0% of the ratios were between 10 and 14. In 
45.6% of the patients, midazolam was tapered in a timeframe of 24 hours from substitu-
tion, in agreement with the protocol. In 32.9%, intravenous midazolam was discontinued 
before 24 hours and in 21.5%, simultaneous administration of intravenous midazolam 
and oral lorazepam continued for more than 24 hours. 
DISCUSSION
Our midazolam to lorazepam switch protocol to prevent IWS appeared to be effective in the 
majority of patients, as no increase in the occurrence of IWS was detected. Nevertheless, 
at least 20% of patients still experienced withdrawal symptoms, while almost 40% showed 
signs of oversedation in the early stages after conversion. 
Based upon the available SOS scores, the incidence of IWS was similar before and after 
conversion to lorazepam. A limitation is that only about half of the patients were scored for 
withdrawal, making the results hard to extrapolate. When we assume that the exhibition 
of IWS symptoms is a trigger to start collecting SOS scores, the absence of SOS scores 
may be seen as a sign that the patients were doing well, but this needs to be verified in a 
prospective setting. Furthermore, the SOS scale cannot discriminate between opioid and 
benzodiazepine withdrawal. This means that the reported IWS cannot unequivocally be 
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attributed to benzodiazepine withdrawal, especially in the eight patients where morphine 
was tapered simultaneously. Nevertheless, we did not observe an increase in IWS after the 
conversion to lorazepam.
The incidence of IWS in critically ill children has been reported to range from 13%-87% 
(8-19). This large variation was the result of small sample sizes, a large variety in often 
unvalidated assessment methods and non-standardised or absent sedation protocols 
and weaning regimens. Identified risk factors for IWS are cumulative doses of midazolam 
greater than 40 mg/kg (8, 11), infusion of opioids and benzodiazepines for more than five 
days (8, 11, 13), and midazolam infusion rates above 0.35-0.42 mg/kg/h (18, 19). Taking 
into consideration the clinical patient characteristics, such as the high cumulative doses of 
midazolam and long PICU stays, it becomes apparent that the patients in our cohort were 
at high risk for developing IWS. In our retrospective cohort, based upon the available SOS 
scores, IWS was diagnosed in one-fifth of the patients, both before and after substitution. 
The majority of the collected COMFORT-B scores were within the target range for adequate 
sedation, with a tendency towards more oversedation post-substitution. This could 
suggest supratherapeutic dosages of sedatives, especially during the first 24 hours in which 
midazolam and lorazepam were simultaneously administered. To put these findings into 
perspective, COMFORT-B scores of nine and 10 could be the result of a comfortably asleep 
child with normal muscle and facial tone and is not necessarily indicative of an unsafe 
situation. Considering it may take a number of days to reach steady-state plasma levels of 
lorazepam due to its long half-life, it seems rational to start with lorazepam while phasing 
out midazolam to ensure adequate exposure. The absence of apnoeas and flumazenil 
administration during the study period provides evidence that the combined blood levels 
of benzodiazepines were not within the toxic range. It is notable that several patients 
experienced both oversedation and withdrawal after substitution, which illustrates the 
complexity of managing IWS. The comparison of rescue administrations of midazolam 
and other sedatives yielded no statistically significant results. 
The lorazepam dose calculation was based on the relative half-life and potency of lorazepam 
versus midazolam, as determined in adult patients, and irrespective of individual patient 
characteristics. Lorazepam is primarily metabolised through conjugation with glucuronic 
acid by multiple hepatic UDP-glucuronosyltransferase enzymes, to inactive metabolites. 
The maturation rates of involved enzyme systems differ between the subtypes, but 
may well extend beyond the age of two years, based upon gene expression data and in 
vivo experiments (20, 21). Paediatric pharmacokinetic data after the oral administration 
of lorazepam are unavailable. At the moment, there are insufficient data available to 
establish an age-dependent conversion factor. Midazolam pharmacokinetics in paediatric 
patients are well studied and are highly dependent on CYP3A4 activity. High blood levels 
of midazolam might be caused by delayed clearance due to immature metabolism 
at a neonatal age (22), ongoing inflammation and critical illness (23), co-medication, 
accumulation of its active metabolites after prolonged use (19) or renal insufficiency (24). 
None of these factors are currently considered in the dose calculation.
This retrospective analysis of a weaning strategy reflects clinical practice in patients in a 
complex, intensive care setting. We acknowledge that our study had several limitations. 
Although COMFORT-B scores were taken regularly, we found that SOS scores were 
underreported. In addition, the lorazepam dose calculation in some patients was 
based upon the midazolam dosage rate at the moment of conversion instead of the 
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cumulative dose of the last 24 hours, resulting in different dosing strategies. Since 2017, a 
lorazepam extemporaneous oral liquid of 1 mg/ml has been available (25). As a result, oral 
administration of injection fluid is no longer applied and capsules are no longer used. The 
dose conversion is now checked by the attending pharmacist. One further limitation was 
that the concomitant use of other central nervous depressants was common during PICU 
stays in our study and this hindered the attribution of the observations to the conversion 
from midazolam to lorazepam. 
In the past two decades, considerable progress has been made in recognising the need 
for weaning-off sedation strategies in PICUs. Risk factors for the development of IWS have 
been identified and scoring systems have been validated and implemented to monitor 
the patients. This study was the first to specifically address the use of oral lorazepam in the 
weaning-off sedation strategy in PICU patients. 
CONCLUSION
The weaning protocol for sedatives using lorazepam did not increase the incidence of 
IWS and appeared to be safe. A better understanding of the factors that explain variations 
in both pharmacokinetics and pharmacodynamics may help us to further tailor weaning 
strategies to the individual patient. 
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Children deserve access to medicines that have been specifically developed and 
researched for use in young patients. The measures that were put in place with the 
Paediatric Regulation have ensured that paediatric medicine development became an 
integral part of the overall development of medicines. However, for off-patent medicines, 
these measures have not been sufficient.
The research combined in this thesis aimes to improve paediatric pharmacotherapy 
by developing a standardised approach for the design and evaluation of pharmacy-
compounded oral liquids of off-patents medicines. A multidisciplinary approach was 
sought with the intention to establish a framework for current and future paediatric 
formulation development, combining the expertise of pharmacists of the Laboratory of 
Dutch Pharmacists (LNA) and the Erasmus MC hospital pharmacy, and of clinicians of the 
Sophia Children’s Hospital. Part 1 of this thesis consisted of a general introduction to the 
topic and an exploration of unmet needs and common practices relating to paediatric 
formulations in clinical practice. In part 2 we described the formulation development of 
two compounds chosen to represent both water-soluble and water-insoluble drugs, and 
for which an unmet need existed in paediatric practice. We presented in vitro methods to 
simulate in vivo performance of the developed liquids. In part 3 the results of the clinical 
studies were presented, in which the developed liquids were evaluated in both adult 
volunteers as well as the paediatric target population.
MAIN FINDINGS
Part 1: A large gap still exists between paediatric needs and the availability 
of medicines with an age-appropriate formulation. Pharmacy-compounded, 
unlicensed formulations remain essential to fulfil these needs. Manipulation of oral 
dosage forms is common practice and there is a need for improvement of information 
provision regarding manipulation towards parents/caregivers.
Part 1 of this thesis was funded by the Royal Dutch Pharmacists Association as part of the 
research programme of 2017. We identified the issues surrounding paediatric formulations 
in daily clinical practice, with the aim to guide future paediatric formulation development, 
and improve current information provision to parents and healthcare professionals 
regarding paediatric drug administration. Based on the dispensing data of the Sophia 
Children’s Hospital, we identified a profound gap in the availability of age-appropriate 
formulations, especially for neonates and infants at the intensive care, for which 42% 
of the dispensed products were considered unsuitable,  according to the acceptability 
matrix from the ‘Reflection paper on formulations of choice for the paediatric population’ 
(1).  Our data show that pharmacy compounding in the treatment of paediatric patients 
remains essential, as more than half of the dispensed products did not have a marketing 
authorisation. A survey across Dutch paediatric hospital pharmacies revealed that the use 
of pharmacy-compounded products was widespread, and that almost half of the most 
commonly used compounded products  in the Netherlands were not included in the EMA 
inventory of paediatric needs.
 As part of the suitability assessment, exposure to potential toxic excipients  was calculated 
based upon dosage and excipients concentration and compared with EMA limits for safe 
exposure. We found that possible toxic exposure was not limited to only neonatal ICU 
patients, but was relevant in children up to the age of four years. Efforts should be made 
to reduce the exposure to potentially harmful excipients, by avoiding or substituting non-
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essential medicines, and improving the composition of essential medicines. 
In chapter 3 we  identified the problems in drug administrations to children, experienced 
by both parents/caregivers, as well as by nurses, by determining the extent, reasons 
and methods used for drug manipulation. The gap in availability of age-appropriate 
formulations was reflected in the results from this chapter. Manipulation of oral dosage 
forms was common practice among both parents/caregivers as well as nurses in a 
paediatric hospital, with a similar prevalence of 30% in the outpatient setting versus 37% 
in the inpatient setting. Manipulation by parents/caregivers occurred mainly to achieve 
taste and dose adjustment, whilst nurses most often used manipulation for administration 
through a feeding tube and size reduction. This difference probably results from the more 
extensive formulary of the inpatient pharmacy, which allows for more precise dosing with 
compounded liquids and capsules of different strengths, and the higher prevalence of 
feeding tubes in the inpatient setting. 
The most unexpected result from the survey described in chapter 3 was the low 
dissemination of information regarding the correct method of manipulation from the 
pharmacy towards both parents/caregivers and nurses. Even though this information is 
available to pharmacies in the Dutch reference work Oralia VTGM, and within the hospital 
to the nurses through every workstation, only half of the interviewed parents/caregivers 
stated to have received their information from the pharmacy, and only 28% of the nurses 
consulted the pharmacy-provided information. Aside from this finding, many of the 
recommendations in the Oralia VTGM are based on practical experience, rather than 
research.
Part 2 The concept to develop two types of formulations, for water-soluble and 
water-insoluble drug compounds, appeared fertile for improving the availability 
of age-appropriate, paediatric formulations for off-patent drugs. Amlodipine 
and lorazepam can be compounded into stable oral clear solutions using simple 
techniques and safe excipients.
The second part of this thesis presented results from the ZonMw project that aimed to 
integrate pharmaceutical development of paediatric formulations and the consecutive 
clinical testing in the target population. Because of the need for flexible dosing and ease 
of administration, oral liquids were the preferred dosage form to be developed, and 
amlodipine and lorazepam were chosen to serve as proof of concept, and because of the 
unmet need in paediatric practice. As evidenced by chapter four and five of this thesis, 
the close cooperation with the LNA resulted in two feasible new formulations, both using 
safe and readily available excipients, requiring simple compounding techniques, and 
providing good stability when stored refrigerated. 
Next to the pharmaceutical development , we explored the use of biopharmaceutical 
methods to predict in vivo performance of medicines in paediatric populations, facilitated 
by the University of Bath. With experiments designed to reflect clinical practice in the 
Sophia Children’s Hospital, the impact of patient related factors on drug performance was 
studied, using drug solubility in paediatric biorelevant media and biorelevant dissolution. 
Ideally, these in vitro predictive methods, combined with in silico models, will in the future 
replace in vivo experiments and clinical trials in paediatric patients. 
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Part 3 The theoretical approach from part two resulted in clinically useful 
formulations. The amlodipine oral solution is bioequivalent to amlodipine 
tablets, and both the amlodipine and lorazepam oral solutions provide high oral 
bioavailability
The third part of this thesis consists largely of clinical research. As part of the ZonMw 
project, both formulations were further studied in the target population to assess 
pharmacokinetic parameters, safety issues and acceptability. For amlodipine, we chose to 
first compare the performance of the oral solution to originator tablets in adult volunteers 
in a bioequivalence study. As expected, the oral solution and tablets were bioequivalent, 
with only a statistically different time to maximum concentration. With the slow and passive 
absorption of amlodipine, this difference is expected to  have no clinical relevant effect on 
blood pressure control. The consecutive population pharmacokinetic study in paediatric 
patients confirmed the oral solution to be a good treatment option for younger paediatric 
patients with adequate acceptability. The population pharmacokinetic study of the 
lorazepam oral solution in paediatric intensive care patients was the first study to evaluate 
oral lorazepam in paediatric patients. Using a population pharmacokinetic approach and 
non-linear mixed effects modelling, we demonstrated high oral bioavailability of 80% for 
the lorazepam oral solution.
METHODOLOGICAL CONSIDERATIONS
Strengths and limitations
The major strengths of the studies included in this thesis relate to
• the large datasets collected at the Sophia Children’s Hospital, representing the entire 
paediatric age range and all major and minor specialties
• the multidisciplinary approach, combining the expertise of pharmacist and 
paediatricians,  and based on clinical practice of the largest paediatric hospital of The 
Netherlands
• the conformity of the results of the clinical trials with our expectations and available 
literature
One of the main strengths of this thesis generates from the multidisciplinary approach, 
which ultimately resulted in the development of two paediatric oral solutions, which are 
supported by clinical data from the target population, and can be considered standard 
of care following incorporation into the Formulary of Dutch Pharmacists (FNA). The 
composition, method of preparation and shelf-life make both oral solutions suitable 
for large-scale production as well as extemporaneous compounding. The formulation 
design and validation was supported by the experts of the LNA, and the Department 
of Pharmaceutical Technology and Biopharmacy of the University of Groningen. The 
collaboration with the University of Bath showed that in vitro biopharmaceutical tools can 
be useful for studying drug performance in children. The straightforward experimental 
setups make it possible to address numerous different administration scenarios, which 
would not be feasible or ethical in pharmacokinetic studies in children. 
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The clinical phase of the ZonMw project was designed to perform patient-based research 
in the target paediatric population, aiming to elucidate pharmacokinetic, acceptability 
and safety parameters of the developed oral solutions. Both paediatric trials were designed 
in close collaboration with the clinicians, and the lorazepam trial profited from the well-
established clinical research structure of the paediatric intensive care unit. We were able 
to include patients in a difficult setting, and as young as 4 weeks old. Furthermore, the 
clinical trial results were in accordance with our expectations based on the physical-
chemical characteristics of the compounds and previously reported studies in both adults 
and children. 
The most important general limitations of the studies included in this thesis relate to
• gaps in the knowledge base regarding acceptability of medicines to paediatric 
populations
• a knowledge gap concerning gastro-intestinal physiology in paediatric patients, 
limiting the predictive value of the biopharmaceutical in vitro experiments
• due to refusal of the parents (amlodipine) and absence of an arterial line (lorazepam), 
inclusion rates in the paediatric trials were low
Guidance issued by the European Medicines Agency states that patient acceptability 
must be an integral part of paediatric formulation development and be described in the 
paediatric investigation plan (PIP) (2), but before this guidance came into effect in 2014, 
there was no requirement for medicines to be demonstrated to be acceptable to children. 
The evidence base concerning what is acceptable to paediatric patients is therefore limited 
and standard methods or criteria that define what is considered acceptable have not 
been determined (3). The suitability assessment in chapter 2 is based on the acceptability 
matrix from the ‘Reflection paper on formulations of choice for the paediatric population’ 
by the EMA (1), but the matrix was based on expert opinion rather than sound scientific 
evidence, which limits the validity of the results. 
The solubility and dissolution experiments presented in chapter 6 explore 
biopharmaceutical tools that can be used to predict in vivo drug performance. Ideally, 
the results obtained from in vitro dissolution experiments would be integrated into more 
complex in silico prediction models. This physiologically based pharmacokinetic (PBPK) 
modelling and simulation is already commonly used in formulation development/bridging 
for adult medicines and provides a promising tool for paediatric in vivo drug performance 
prediction, provided we gain a better understanding of the developmental changes of 
the gastrointestinal tract in the paediatric population (4). Furthermore, validation of the 
biopharmaceutical methods requires rich PK data, which are often not available.
In the lorazepam trial, removal of the arterial line to prevent infection and/or discharge 
to the general ward often resulted in eligible patients not participating in the study. For 
the amlodipine trial, refusal by the parents due to the burden of study procedures was 
common. This led to lower than expected inclusion rates, which is commonly referred to 
as Lasagna’s Law, where “the incidence of patient availability sharply decreases when a 
clinical trial begins and returns to its original level as soon as the trial is completed” (5). 
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Study endpoints and feasible trial design 
Initially, the amlodipine paediatric trial was designed to compare formulation performance 
of tablets and our oral solution. From in vitro studies and adult data we already knew that 
the oral pharmacokinetics of amlodipine are minimally influenced by the dosage form (6), 
which was confirmed in our bioequivalence study in healthy adults. Also, ICH E11 clearly 
states that relative bioavailability comparisons of paediatric formulations with the adult 
oral formulation should be done in adults, unless the drug is unsafe in healthy volunteers, 
the PK of the compound is different in patients, or the PK of the compound is different in 
children (7). Since amlodipine is absorbed by slow passive diffusion across the intestinal 
membrane, differences in intestinal drug absorption between adults and paediatric 
patients are unlikely. A comparison of formulation performance in paediatric patients 
was therefore in hindsight not indicated. With an amendment, we changed the focus of 
the trial to elucidation of the pharmacokinetic parameters of amlodipine in children, with 
secondary endpoints regarding acceptability, pharmacodynamics (blood pressure) and 
clinical covariates, but ultimately only acceptability was a formulation specific outcome. 
During the conduct of the study, it became clear that the study procedures and switching 
to study medication were considered a burden to many of the eligible patients and 
parents, and were reasons not to participate in the trial. Consequently, inclusion of study 
participants did not reach the goal of 20 patients. 
Pharmacokinetic data of amlodipine in children under the age of six years are still 
warranted, but are formulation independent, which we were not aware of at the start 
of the project. This provides the opportunity to collect them in less invasive manner, 
for instance, from renal transplant patients that regularly undergo blood sampling for 
therapeutic drug monitoring of immunosuppressants. To collect pharmacokinetic data 
from the youngest patients, study procedures could be limited to collection of capillary 
blood samples, which is for many patients a regular procedure with a low burden. 
The lorazepam trial was well designed for its purpose of determining oral bioavailability, 
which we accomplished with inclusion of only eight patients. Even though there were 
no indications that lorazepam would perform different in paediatric patients compared 
to adults, we have now confirmed this in a relatively non-invasive trial in the relevant 
population. From personal experience, inclusion rates could have been improved with a 
slightly different approach, which was implemented with the second study amendment. 
Introducing the study to the parents became easier when the lorazepam oral solution 
became standard of care and replaced the previously compounded 0.1 mg capsules. Initially, 
the study was designed to include only patients who were yet to start with lorazepam, 
but this was actually no requirement for the determination of oral bioavailability when 
using non-linear mixed effects modelling. The single administration of an intravenous 
dose was no objection for any of the parents. Unfortunately, the presence of an arterial 
line proved to be essential for the successful collection of blood samples, and was a factor 
we could not influence. It shows how complicated clinical research in paediatric patients 
can be. The acceptability of the oral solution could not be assessed in this population, 
as all patients received it through a feeding tube. It is expected that the formulation will 
incidentally be applied in the outpatients setting, where this formulation property will 
become more relevant.
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RECOMMENDATIONS
Recommendations for practice
Even though no immediate risks were identified in the survey regarding manipulation, 
pharmacist should improve their efforts in proactively informing parents/caregivers 
about drug manipulation and administration, and this should include both verbal as 
well as written information. The Royal Dutch Pharmacists Association could support this 
effort with the development of patient-oriented, generic information leaflets regarding 
manipulation techniques, most importantly dose adjustment of solid dosage forms.
Recommendations for policy
As shown in the amlodipine trial, the availability a suitable formulation can greatly 
improve the ease of drug administration to children, and subsequently, have an influence 
on treatment outcome. It is essential that pharmacists keep investing in the development 
of suitable formulations for paediatric patients, in collaboration with paediatricians, the 
LNA and compounding pharmacies within The Netherlands. The special interest group 
‘paediatrics’ of the Dutch Association of Hospital Pharmacists should take the lead in this. 
The efforts of the European Pharmacopoeia Commission in the compilation of a pan-
European Paediatric Formulary should be highly supported. Information collected in 
the Formulary of Dutch Pharmacists could be valuable. Further financial support from 
the European Union could accelerate the efforts and is necessary for standardisation, 
validation and filling the gaps in information, and would, in our opinion, be well-spent. 
Standard methods or criteria that define what is considered acceptable to children have 
not been determined (3). The approach that was chosen in chapter eight to study the 
acceptability of the amlodipine oral liquid is generally considered suitable, but the lack 
of standardisation makes comparing results difficult. A lack of knowledge about what is 
currently considered to be acceptable to paediatric patients hinders the development of 
acceptable, age-appropriate medicines. Therefore, EMA guidance on how to perform and 
interpret acceptability studies in paediatric patients is highly warranted.
Recommendations for future research
The oral solutions presented in part 2 of this thesis were meant to serve as proof of 
concept, and the drug substances were chosen to represent water-soluble and water-
insoluble compounds. The approach that was chosen to process the poorly water-soluble 
lorazepam, using a mixture of organic solvents, should be tested for other drug substances 
with poor aqueous solubility. The readily available and cheap excipients, and the relatively 
easy compounding method, could possibly provide a solution for a large range of difficult 
to process drug substances. Compound selection should focus on BCS class II and class IV 
drugs. 
The paediatric population remains a difficult population to study. Clinical trials are 
expensive, and resources should be allocated wisely. Many trials fail or are not completed, 
and the reasons for that are several (8). It is very likely that paediatric drug development 
will benefit from European collaboration, as envisioned by the Connect4Children 
collaborative network for European clinical trials for children, which aims to generate a 
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sustainable infrastructure that optimises the delivery of clinical trials in children. 
In vitro biopharmaceutical techniques, combined with in silico models, have the potential 
to replace in vivo experiments and clinical trials, but there is still a knowledge gap 
concerning GI physiology in paediatric patients. Aside from the factors influencing in 
vivo dissolution, specific research is still required on the factors influencing permeability, 
mainly the ontogeny of metabolizing enzymes and drug transporters, to better predict 
oral drug absorption in this population. Access to existing paediatric rich pharmacokinetic 
data is required to validate the biopharmaceutical tools. 
In this thesis we have shown that for off-patent medicines, for which there is no economics 
basis for licensing, pharmacy compounding may offer a highly feasible solution to provide 
acceptable and dose flexible pharmacotherapy for children.
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Geneesmiddelonderzoek bij kinderen heeft lange tijd te weinig aandacht gehad. Tot ver 
in de 20e eeuw was men van mening dat kinderen niet zouden mogen deelnemen aan 
klinisch geneesmiddelonderzoek, met name vanwege ethische bezwaren. Tegenwoordig 
is de algemene consensus dat kinderen recht hebben op toegang tot geneesmiddelen 
die specifiek voor hen ontwikkeld en onderzocht zijn. Dat neemt niet weg dat er nog 
talloze obstakels te overbruggen zijn.  Met name de heterogeniteit binnen de vaak toch al 
kleine studiepopulatie, maakt het opzetten van goede kindergeneesmiddelonderzoeken 
een uitdaging. Daarnaast maken de veelal kleine doelpopulaties het economisch 
onaantrekkelijk voor bedrijven om te investeren in geneesmiddelregistraties specifiek 
voor kinderen. 
Om dit probleem aan te pakken werd ,in navolging van de Verenigde Staten, in 2006 in 
de Europese Unie de Paediatric Regulation aangenomen, wat ertoe heeft geleid dat in de 
jaren 2007-2016 meer dan 260 nieuwe geneesmiddelen en indicaties voor gebruik door 
kinderen zijn goedgekeurd door de European Medicines Agency (EMA). Farmaceutische 
bedrijven beschouwen de ontwikkeling van kindergeneesmiddelen nu als integraal 
onderdeel van het ontwikkeltraject van een geneesmiddel. Hier tegenover staat dat de 
ontwikkeling van middelen die uit patent zijn is achtergebleven. 
Er zijn veel ‘oudere’ geneesmiddelen die een belangrijke plaats hebben in de behandeling 
van kinderen, maar vaak is hiervan geen geschikte toedieningsvorm beschikbaar. Met 
name de acceptatie door de patiënt (o.a. op basis van smaak) en de dosisflexibiliteit vormen 
vaak een probleem. Apothekers kunnen in een dergelijk geval zelf een geneesmiddel 
bereiden, zogenaamde magistrale bereidingen. Dit heeft vaak de voorkeur boven het 
manipuleren van bestaande toedieningsvormen, zoals het vermalen van tabletten, of 
toediening met dranken of voeding. Magistrale bereidingen worden in Nederland meestal 
volgens standaardvoorschriften gemaakt (Formularium der Nederlandse Apothekers 
(FNA)) hoewel dat niet verplicht is. FNA-voorschriften worden farmaceutisch-technisch 
uitgebreid onderzocht en wanneer deze onder de juiste omstandigheden worden bereid 
kan de kwaliteit gegarandeerd worden. Buiten het FNA worden er echter nog talloze niet-
gestandaarde bereidingen toegepast die qua samenstelling sterk kunnen verschillen 
tussen de verschillende kinderziekenhuizen. Het is de vraag of het ontwerp van deze 
producten optimaal is voor toepassing bij kinderen. 
Deel 1 Kinderformuleringen in de dagelijkse klinische praktijk
In hoofdstuk 2 van dit proefschrift hebben we in kaart gebracht welke plaats de 
apotheekbereiding inneemt in de behandeling van klinische patiënten van het Erasmus 
MC Sophia Kinderziekenhuis. Met name neonaten, zowel prematuur als aterm geboren, 
werden vaak behandeld met eigen bereidingen, die meer dan de helft van de afgeleverde 
geneesmiddelen vormden. Ook werd duidelijk dat er in Nederland veel eigen bereidingen 
worden toegepast die niet in de EMA inventory of paediatric needs zijn opgenomen, terwijl 
deze middelen dus kennelijk wel nodig zijn. Naast de focus op apotheekbereidingen 
hebben we in dit hoofdstuk ook onderzocht hoe groot de blootstelling aan potentieel 
schadelijke hulpstoffen was bij klinische patiënten, met een focus op vloeibare 
geneesmiddelen. Hieruit bleek dat er verbeteringen te behalen vielen door middel van 
substitutie van bepaalde producten en het verbeteren van de samenstelling van bepaalde 
eigen bereidingen.
Als er geen goede toedieningsvorm beschikbaar is, wordt vaak teruggevallen op 
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manipulatie van de toedieningsvorm door ouders en/of zorgverleners, bijvoorbeeld door 
tabletten te vermalen, ze op te oplossen, te breken of ze vermengd met melk of eten toe 
te dienen. De consequenties van het manipuleren op de effectiviteit en veiligheid van 
het geneesmiddel zijn niet duidelijk of soms zelfs bewezen schadelijk. Uit het onderzoek 
beschreven in hoofdstuk 3 onder poliklinische patiënten in het Erasmus MC Sophia 
Kinderziekenhuis bleek 45% van de ondervraagde ouders orale medicatie te manipuleren 
voor toediening. In de praktijk zijn instructies aan ouders over manipulatie-mogelijkheden 
vaak beperkt, niet uniform en veelal niet goed onderbouwd. Eén van de aanbevelingen 
die uit dit proefschrift volgen is dan ook om deze informatievoorziening door apothekers 
te verbeteren, en waar nodig deze informatie ook te genereren. 
Deel 2 Farmaceutische ontwikkeling en in vitro evaluatie
Er is een grote behoefte aan goed onderzochte, kindvriendelijke, orale geneesmiddelen, 
die bij voorkeur een grote dosisflexibiliteit hebben. In het kader van het programma 
Priority Medicines voor Kinderen heeft ZonMW hiervoor een subsidie verstrekt, waarmee 
de ontwikkeling van twee dranken is bekostigd. Uitgangspunt was hierbij dat de 
formuleringen toepasbaar zouden zijn voor meerdere geneesmiddelen. Amlodipine en 
lorazepam zijn vervolgens gekozen als modelstoffen voor water-oplosbare en niet water-
oplosbare geneesmiddelen.
In samenwerking met het Laboratorium der Nederlandse Apothekers (LNA) werd 
gestart met de farmaceutische ontwikkeling van twee dranken, rekening houdend 
met de beperkte hoeveelheid hulpstoffen die veilig gebruikt kunnen worden en 
specifieke aspecten zoals smaak (acceptatie). Om doseerfouten van potente middelen te 
voorkomen gaat de voorkeur uit naar een heldere drank boven een suspensie, omdat 
bij een suspensie omschudden nodig is voor dosis homogeniteit. In de praktijk zijn 
ernstige fouten voorgekomen bij toepassing van inhomogene suspensies. Op basis van 
de fysisch-chemische eigenschappen (oplosbaarheid, pKa) van het geneesmiddel is 
gekeken welke oplosvloeistoffen mogelijk waren, welke pH nagestreefd moest worden 
en welke hulpstoffen daarbij noodzakelijk waren. Vervolgens is houdbaarheidsonderzoek 
uitgevoerd met gevalideerde analysemethodes. Dit heeft uiteindelijk geresulteerd 
in de ontwikkeling van een amlodipinedrank van 0,5 mg/ml (hoofdstuk 4) en een 
lorazepamdrank van 1 mg/ml (hoofdstuk 5). 
Naast de ontwikkeling van de twee dranken is in samenwerking met de Universiteit 
van Bath onderzoek gedaan naar in vitro modellen die de blootstelling aan orale 
geneesmiddelen bij kinderen kunnen voorspellen. Hierbij is de vrijgifte van twee 
geneesmiddelen onderzocht in nagebootste vloeistoffen uit het maagdarmkanaal. 
Hiermee kan een voorspelling worden gedaan over de uiteindelijke blootstelling bij 
toediening aan patiënten. Het is de bedoeling dat, in de toekomst, deze modellen het in 
vivo onderzoek bij kinderen grotendeels overbodig maken. 
Deel 3 Klinische toepassing van de formuleringen
Om de blootstelling aan twee verschillende varianten van hetzelfde geneesmiddel te 
vergelijken wordt bio-equivalentieonderzoek bij volwassen vrijwilligers uitgevoerd. De 
farmacokinetische parameters area under the curve en de maximale plasmaconcentratie 
na een eenmalige dosis van het onderzoeksmiddel en een referentiemiddel worden 
vergeleken, als het verschil binnen bepaalde grenzen valt worden de middelen 
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beschouwd als bio-equivalent. Uit de bio-equivalentiestudie met amlodipine beschreven 
in hoofdstuk 7 bleek dat de drank en tabletten gelijkwaardig waren. Voor lorazepam is geen 
bio-equivalentieonderzoek uitgevoerd, omdat er geen relevant, bij kinderen toegepast 
product was om mee te vergelijken. Gezien de fysisch-chemische eigenschappen van 
lorazepam is er ook geen groot verschil te verwachten tussen verschillende producten. 
De volgende fase was de toepassing van de dranken bij kinderen, waarbij farmacokinetiek 
(PK), farmacodynamiek (PD), bijwerkingen en de acceptatie in kaart gebracht werden. 
Voor amlodipine werd onderzoek uitgevoerd bij patiënten (6 maanden-11 jaar) met 
hypertensie, voor lorazepam bij kinder-IC-patiënten (0-11 jaar). Alle geïncludeerde 
patiënten gebruikten het geneesmiddel om klinische redenen. 
Met software om patiëntendata te modelleren (Non-lineair Mixed Effects Modeling, 
NONMEM®) was het mogelijk om ook met beperkte datasets en wisselende 
bloedafnametijdstippen resultaten te genereren. Deze lieten zien dat beide dranken 
voorzagen in adequate bloedspiegels, er werden geen ernstige bijwerkingen 
waargenomen gerelateerd aan de dranken en ze werden goed geaccepteerd door de 
doelgroep. Bij de lorazepamstudie was de doelgroep een kwetsbare, instabiele groep op 
de IC met veel co-morbiditeit en co-medicatie, maar ouders bleken toch open te staan 
voor deelname van hun kind aan onderzoek.
De laatste jaren wordt het belang van goede toedieningsvormen van geneesmiddelen 
voor kinderen steeds meer erkend. Apotheekbereidingen spelen hierbij een belangrijke 
rol vanwege het ontbreken van handelsproducten. Optimalisatie en standaardisatie 
van deze bereidingen is noodzakelijk uit oogpunt van kwaliteit. Bij de ontwikkeling 
moet aandacht zijn voor dosisflexibiliteit en de geschiktheid voor neonaten en jonge 
kinderen, met name ten aanzien van hulpstoffen. Een samenwerking tussen kinderartsen 
en apothekers is hierbij belangrijk om de behoefte in de klinische praktijk adequaat te 
kunnen invullen. In dit onderzoek heeft dat geleid tot de succesvolle ontwikkeling en 
toepassing  van amlodipine- en lorazepamdrank bij kinderen.
Summary
Drug development for children has long been a neglected area compared to adult 
drug development. Until late into the 20th century, the general view was that children 
should not participate in clinical trials, particularly because of ethical concerns. Today, the 
general consensus is that children are entitled to medicines that have been specifically 
developed and researched for them. Nevertheless, many barriers still remain. In particular, 
the heterogeneity within the already very small study population makes setting up good 
paediatric drug researches a challenge. In addition, the mostly small target populations 
make it economically unattractive for companies to invest in drug registrations 
specifically for children. To address these issues, the Paediatric Regulation was adopted 
in the European Union in 2006, leading to more than 260 new medicines and indications 
for use by children approved by the European Medicines Agency (EMA) in 2007-2016. 
Pharmaceutical companies now consider the development of paediatric medicines 
as an integral part of the development process of a medicine. On the other hand, the 
development of off-patent medicines lags behind.
There are many ‘older’ medicines that have an important place in the treatment of 
children, but often no suitable dosage form is available. In particular, acceptance by the 
patient (e.g. based on taste) and dose flexibility are a problem. Pharmacists can in such a 
case compound a medicine, so-called magistral preparations. This is often preferred over 
manipulating existing dosage forms, such as grinding of tablets, or administration with 
drinks or food. In the Netherlands, magistral preparations are usually made according 
to standard instructions (Formulary of Dutch Pharmacists (FNA)), although this is not 
mandatory. FNA products are extensively studied regarding pharmaceutical quality, and 
when they are prepared under the right conditions the quality can be assured. However, 
numerous non-standard preparations are still being used outside the FNA, which differ 
greatly in composition between the different children’s hospitals. The question is whether 
the design of these products is optimal for application in children.
Part 1 Paediatric formulations in daily clinical practice
In chapter 2 of this thesis we demonstrated the importance of pharmacy preparation in the 
treatment of clinical patients at the Erasmus MC Sophia Children’s Hospital. In particular, 
neonates, born prematurely and term, were often treated with pharmacy preparations, 
which accounted for more than half of the medicines dispensed. It also became clear 
that many pharmacy preparations used in the Netherlands are not included in the EMA 
inventory or paediatric needs, while these medicines are obviously needed. In addition 
to the focus on pharmacy preparations, in this chapter we also investigated the extent 
of exposure to potentially harmful excipients in clinical patients, with a focus on liquid 
medicines. This showed that improvements could be achieved by substituting certain 
products and improving the composition of certain pharmacy preparations.
If a suitable dosage form is not available, parents and/or caregivers often rely on 
manipulation of the dosage form, for example by grinding tablets, dissolving them, 
breaking them or mixing them with milk or food. The consequences of manipulating 
on the effectiveness and safety of the drug are not clear, or even proven to be harmful. 
From the research described in chapter 3 among outpatients at the Erasmus MC Sophia 
Children’s Hospital, 45% of the parents participating in the questionnaire indicated to 
manipulate oral medication for administration. In practice, instructions to parents about 
manipulation options are often limited, not uniform and often not well substantiated. 
One of the recommendations that follows from this thesis is therefore to improve this 
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information provision by pharmacists and, where necessary, to generate this information.
Part 2 Pharmaceutical development and in vitro evaluation
There is a great need for well-studied, child-friendly, oral drugs, which preferably have a 
large dose flexibility. Under the ZonMW Priority Medicines program for children, ZonMW 
has provided a subsidy, which has funded the development of two liquid formulations. 
The starting point was that the composition of the formulations would be suitable for 
several drugs. Amlodipine and lorazepam were then chosen as model compounds for 
water-soluble and non-water-soluble drugs.
In collaboration with the Laboratory of Dutch Pharmacists (LNA), the pharmaceutical 
development of two liquid formulations was started, taking into account the limited 
amount of excipients that can be safely used, and specific aspects such as taste (acceptance). 
In order to prevent dosing errors of potent agents, preference is given to a clear liquid 
over a suspension, because in a suspension shaking is necessary for dose homogeneity. 
In practice, serious errors have occurred with the use of inhomogeneous suspensions. 
On the basis of the physicochemical properties (solubility, pKa) of the compounds, we 
examined which solvents were possible, which pH had to be sought and which excipients 
were necessary. Subsequently, stability testing was performed using validated analysis 
methods. This ultimately resulted in the development of an amlodipine oral solution of 0.5 
mg/ml (chapter 4) and a lorazepam oral solutions of 1 mg/ml (chapter 5).
In addition to the development of the two liquids, in collaboration with the University of 
Bath research was done into in vitro models that can predict the exposure to oral medicines 
in children. Here, the release of two drugs was investigated in simulated fluids from the 
gastrointestinal tract. This allows a prediction to be made about the drug exposure when 
administered to patients. The intention is that, in the future, these models will largely 
replace in vivo research in children.
Part 3 Clinical application of the formulations
To compare the exposure to two different variants of the same drug, bioequivalence 
testing is performed in adult volunteers. The pharmacokinetic parameters area under 
the curve and the maximum plasma concentration after a single dose of the study drug 
and a reference product are compared, and if the difference falls within certain limits, 
the products are considered bioequivalent. The bioequivalence study with amlodipine 
described in chapter 7 showed that the oral solution and tablets were equivalent. For 
lorazepam, no bioequivalence study was performed, because there was no relevant 
product used in children to compare with. Given the physical-chemical properties of 
lorazepam, no major difference can be expected between different products.
The next phase was studying the formulations in paediatric patients, in which 
pharmacokinetics (PK), pharmacodynamics (PD), side effects and acceptance were 
investigated. For amlodipine, a study was conducted in patients (6 months -11 years) with 
hypertension, for lorazepam in paediatric intensive care patients (0-11 years). All included 
patients used the drug for clinical reasons.
With software to model patient data (Nonlinear Mixed Effects Modeling, NONMEM®), it 
was possible to generate results with limited data sets and changing blood sampling 
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times. These showed that both liquids provided adequate blood levels, no serious side 
effects were observed related to the study drug and the liquids were well accepted by the 
target group. In the lorazepam study, our patients were vulnerable, sometimes unstable 
ICU patients with a lot of co-morbidity and co-medication, but parents turned out to be 
open to participation of their child in research.
In recent years, the importance of suitable dosage forms for children has been increasingly 
recognized. Pharmacy preparations play an important role here because of the lack of 
commercial products. Optimization and standardization of these preparations is necessary 
to guarantee good quality. Dose flexibility and the suitability for neonates and young 
children, particularly with regard to excipients, should be considered in the development 
of formulations for children. A collaboration between paediatricians and pharmacists is 
important in order to adequately fill the need in clinical practice. This research has led 
to the successful development and application of amlodipine and lorazepam liquid 
formulations in children.
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